MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces Infarct Size In Vivo by Fiedler, LR et al.
ArticleMAP4K4 Inhibition Promotes Survival of Human
Stem Cell-Derived Cardiomyocytes and Reduces
Infarct Size In VivoGraphical AbstractHighlightsd Human iPSC-cardiomyocytes were used for MAP4K4 target
validation and drug discovery
d MAP4K4 shRNA protects hiPSC-cardiomyocytes from lethal
oxidative stress
d MAP4K4 inhibitors promote hiPSC-cardiomyocyte survival
and function
d MAP4K4 inhibition markedly reduces cardiac ischemia-
reperfusion injury in miceFiedler et al., 2019, Cell Stem Cell 24, 1–13
April 4, 2019 ª 2019 The Authors. Published by Elsevier Inc.
https://doi.org/10.1016/j.stem.2019.01.013Authors
Lorna R. Fiedler, Kathryn Chapman,
Min Xie, ..., Catherine Tralau-Stewart,





cardiomyocytes to enhance cardiac drug
discovery, Fiedler et al. performed
MAP4K4 target validation by gene
silencing in this human model. MAP4K4
inhibitors augment human
cardiomyocyte viability and function in 2D
culture and 3D engineered heart tissue.
An exemplar successfully reduces infarct
size in proof-of-principle studies in mice.
Please cite this article in press as: Fiedler et al., MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces
Infarct Size In Vivo, Cell Stem Cell (2019), https://doi.org/10.1016/j.stem.2019.01.013Cell Stem Cell
ArticleMAP4K4 Inhibition Promotes Survival
of Human Stem Cell-Derived Cardiomyocytes
and Reduces Infarct Size In Vivo
Lorna R. Fiedler,1,8,20 Kathryn Chapman,2,3,4,20 Min Xie,5,17,20 Evie Maifoshie,1,21 Micaela Jenkins,1,21
Pelin Arabacilar Golforoush,1,21 Mohamed Bellahcene,1,21 Michela Noseda,1 Do¨rte Faust,1,9 Ashley Jarvis,4,11
Gary Newton,4 Marta Abreu Paiva,1,12 Mutsuo Harada,1,13 Daniel J. Stuckey,1,15 Weihua Song,1 Josef Habib,1,10
Priyanka Narasimham,4 Rehan Aqil,4 Devika Sanmugalingam,4 Robert Yan,4 Lorenzo Pavanello,4 Motoaki Sano,5,18
SamC.Wang,5,19 Robert D. Sampson,1,14 Sunthar Kanayaganam,1 George E. Taffet,5 Lloyd H.Michael,5 Mark L. Entman,5
Tse-Hua Tan,6,7 Sian E. Harding,1 Caroline M.R. Low,2 Catherine Tralau-Stewart,2,16 Trevor Perrior,4
and Michael D. Schneider1,5,22,*
1British Heart Foundation Centre of Research Excellence, National Heart and Lung Institute, Imperial College London, LondonW12 0NN, UK
2Drug Discovery Centre, Department of Medicine, Imperial College London, London SW7 2AZ, UK
3Department of Surgery and Cancer, Imperial College London, London W12 0NN, UK
4Domainex, Chesterford Research Park, Little Chesterford, Saffron Walden, Essex CB10 1XL, UK
5Michael E. DeBakey Heart Center, Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA
6Immunology Research Center, National Health Research Institutes, Zhunan 35053, Taiwan
7Department of Pathology and Immunology, Baylor College of Medicine, Houston, TX 77030, USA
8Present address: MRC Weatherall Institute for Molecular Medicine, John Radcliffe Hospital, University of Oxford, Oxford OX3 9DS, UK
9Present address: Centre for Therapeutics Discovery, LifeArc, London WC1H 9LT, UK
10Present address: Department of Biomedical Engineering, King’s College London, London SE1 7EH, UK
11Present address: Evotec (UK), Abingdon OX14 4RZ, UK
12Present address: Instituto de Tecnologia Quı´mica e Biolo´gica Anto´nio Xavier, Universidade NOVA de Lisboa, 2780-157 Oeiras, Portugal
13Present address: Department of CardiovascularMedicine, Graduate School of Medicine, TheUniversity of Tokyo, 7-3-1 Hongo, Bunkyo-ku,
Tokyo, Japan
14Present address: Institute of Ophthalmology, University College London, London EC1V 9EL, UK
15Present address: Centre for Advanced Biomedical Imaging, University College London, London WC1E 6DD, UK
16Present address: Clinical & Translational Science Institute, University of California, San Francisco, San Francisco, CA 94158, USA
17Present address: Department of Internal Medicine, University of Alabama, Birmingham, AL 35233, USA
18Present address: Department of Cardiology, Keio University School of Medicine, Tokyo 108-8345, Japan
19Present address: Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
20These authors contributed equally




Heart disease is a paramount cause of global death
and disability. Although cardiomyocyte death plays
a causal role and its suppression would be logical,
no clinical counter-measures target the responsible
intracellular pathways. Therapeutic progress has
been hampered by lack of preclinical human vali-
dation. Mitogen-activated protein kinase kinase
kinase kinase-4 (MAP4K4) is activated in failing
human hearts and relevant rodent models. Using
human induced-pluripotent-stem-cell-derived car-
diomyocytes (hiPSC-CMs) and MAP4K4 gene
silencing, we demonstrate that death induced by
oxidative stress requires MAP4K4. Consequently,
we devised a small-molecule inhibitor, DMX-5804,
that rescues cell survival, mitochondrial function,
and calcium cycling in hiPSC-CMs. As proof of prin-
ciple that drug discovery in hiPSC-CMs may predictCell Stem Cell 24, 1
This is an open access article undefficacy in vivo, DMX-5804 reduces ischemia-reper-
fusion injury in mice by more than 50%.We implicate
MAP4K4 as a well-posed target toward suppressing
human cardiac cell death and highlight the utility of
hiPSC-CMs in drug discovery to enhance cardio-
myocyte survival.
INTRODUCTION
Heart disease remains the single most common cause of death
and disability worldwide and is projected to increase as the pop-
ulation ages, its socio-economic burden consequently rising for
the foreseeable future (GBD 2016 Causes of Death Collabora-
tors, 2017; GBD 2016 DALYs and HALE Collaborators, 2017).
Cardiac muscle cell death is an instrumental component of
both acute ischemic injury and also chronic heart failure, driving
dysfunction of the heart as a biomechanical pump (Dorn, 2009;
Fiedler et al., 2014; Whelan et al., 2010). To date, however, few
human trials for heart disease seek to enhance cardiomyocyte–13, April 4, 2019 ª 2019 The Authors. Published by Elsevier Inc. 1
er the CC BY license (http://creativecommons.org/licenses/by/4.0/).
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have failed between phases I and III, due to the lack of efficacy
(Hausenloy and Yellon, 2015; Heusch, 2013; Lincoff et al.,
2014; Newby et al., 2014; Ottani et al., 2016; Piot et al., 2008).
In 2018 alone, the US Food and Drug Administration approved
13 drugs for cancer, yet none for cardiac indications (US Food
and Drug Administration, 2018). Among other recognized limita-
tions, the conventional pipeline for cardiac drug development
lacks any human preclinical model whatsoever for testing pro-
posed counter-measures (Fordyce et al., 2015; Gromo et al.,
2014). The routine cardiac platforms for predicting efficacy are
inherently flawed, and the creation of novel approvable medi-
cines is ‘‘dead’’ or ‘‘hibernating’’ (Fordyce et al., 2015). In
contrast, for cancer therapeutics, the systematic use of repre-
sentative human cell lines is instrumental to preclinical evalua-
tion of tumor responses, fueling innovation (Wilding and Bodmer,
2014). By offering analogous, scalable, routine access to human
cardiac biology, cardiomyocytes derived from human induced
pluripotent stem cells (hiPSC-CMs) have gained wide accep-
tance as transformative in addressing this unmet need, predict-
ing cardiotoxicity, modeling patient-specific pathways, and
enhancing cardiac target validation and drug discovery as a
partial but auspicious means to improve the in vitro surrogates
(Bellin et al., 2012; Blinova et al., 2018; Burridge et al., 2016;
Cameron et al., 2013; Gintant et al., 2017; Lee et al., 2017b; Liang
et al., 2013; Matsa et al., 2014, 2016; Sharma et al., 2017).
In preclinical models, the molecular and genetic dissection of
cardiac cell death suggests potential nodal control points, among
them, signaling pathways mediated by mitogen-activated protein
kinases (MAPKs), especially Jun N-terminal kinase (JNK) and
p38 (Dorn, 2009; Fiedler et al., 2014;Whelan et al., 2010). Because
the ‘‘terminal’’ MAPKs p38 and JNK receive inputs from multiple
signals, both protective and adverse, it is logical to consider tar-
geting specific proximal kinases that might couple these to cell
death more selectively. MAP kinase kinase kinase kinases
(MAP4Ks) are the most proximal protein kinases in the MAPK
superfamily. MAP4K4 (HPK/GCK-like kinase [HGK]; NCK-
interacting kinase [NIK]) is a serine-threonine kinase related to
Ste20 in S. cerevisiae (Su et al., 1997). Like their yeast ortholog,
the mammalian Ste20 kinases control cell motility, fate, prolifera-
tion, and stress responses (Dan et al., 2001). Deleting MAP4K4 in
mice is embryonic lethal, owing to cell motility defects during
mesoderm patterning (Xue et al., 2001), functions that are
conserved in Drosophila and C. elegans (Chapman et al., 2008)
but obscure its possible function in adult biology. With the cloning
of human MAP4K4 came the first such evidence, coupling pro-
inflammatory cytokines to JNK (Yao et al., 1999). MAP4K4 is
now appreciated as a pivotal mediator of inflammation, cytoskel-
etal function, and, notably, cell death,withwell-established contri-
butions to cancer, diabetes, and neurodegeneration (Chen et al.,
2014; Larhammar et al., 2017; Lee et al., 2017a; Miled et al.,
2005; Vitorino et al., 2015; Yang et al., 2013; Yue et al., 2014).
Presently, MAP4K4 function in the heart is conjectural, but
a pathobiological role is suggested by its engagement of trans-
forming-growth-factor-b-activated kinase-1 (TAK1/MAP3K7),
JNK, and p38 MAPK (Yao et al., 1999; Zohn et al., 2006), three
downstreamMAPKswith reported pro-death functions in cardiac
muscle cells (Fiedler et al., 2014; Jacquet et al., 2008; Zhang
et al., 2000). Consequently, in prioritizing amongproximalMAPKs2 Cell Stem Cell 24, 1–13, April 4, 2019as the basis for a novel small-molecule program, we chose
MAP4K4 as a logical starting point. Here, using hiPSC-CMs as
a human platform for more relevant target validation and com-
pound development, we demonstrateMAP4K4 to be a druggable
target in human cardiac injury. We devised highly selective phar-
macological inhibitors of MAP4K4, demonstrate that inhibiting
MAP4K4 effectively protects human cardiomyocytes from lethal
experimental injury, and take an exemplar forward from human
cardiomyocytes into further proof-of-concept studies in mice.
RESULTS
MAP4K4 Is Activated by Cardiac Death Signals and
Promotes Cardiac Muscle Cell Death
To ascertain the scientific case for inhibiting MAP4K4 in cardiac
cell death, three biological settings first were explored: diseased
human heart tissue; mouse models; and rat cardiomyocytes
(Figures S1–S4). Activation of human cardiacMAP4K4was prev-
alent in chronic heart failure from diverse etiologies, associated
with active (cleaved) caspase-3, a mediator of apoptosis (Fig-
ure S1A), and activation of the MAP3K intermediary, TAK1 (Fig-
ure S1B), which itself can drive cardiac cell death (Zhang et al.,
2000). Likewise, in adult mouse myocardium (Figure S1C) and
cultured rat cardiomyocytes (Figure S1D), MAP4K4 was acti-
vated by clinically relevant provocations that promote cardiac
muscle cell death, including ischemia-reperfusion injury and
H2O2 as the oxidative stress, a pathobiological hallmark of acute
and chronic cardiac disorders (Bertero and Maack, 2018; Brown
and Griendling, 2015). Next, we simulated this increase in
MAP4K4 activity by viral gene transfer in rat ventricular myocytes
(Figure S2). A pro-apoptotic effect of catalytically activeMAP4K4
was confirmed (Figures 2A and 2B), potentially involving TAK1
(Figures S2C and S2D), JNK (Figures S2A, S2D, and S2E), and
the mitochondrial death pathway (Figures S2F and S2G). In adult
mice, cardiomyocyte-restrictedMAP4K4 sensitized themyocar-
dium to otherwise sub-lethal death signals, potentiatingmyocyte
loss, fibrosis, and dysfunction (Myh6-Gnaq: Figures S3A–
S3D; increased workload: Figures S3E–S3H and Table S1).
Conversely, cultured rat cardiomyocytes were protected at least
50% by kinase-dead MAP4K4 (Figure S4A) or MAP4K4 short
hairpin RNA (shRNA) (Figures S4B–S4D). Together, these gain-
of-function, dominant-negative, and loss-of-function studies
suggest a pivotal role for MAP4K4 in cardiac muscle cell death,
albeit with the diverse limitations inherent to non-humanmodels.
MAP4K4 Target Validation in Human Stem Cell-Derived
Cardiomyocytes
To establish whether an equivalent requirement for MAP4K4
also exists in human cardiac muscle cells, we investigated its
role in cardiomyocytes derived from human induced pluripotent
stem cells. Human iPSC-CMs are available more readily and in
higher number than myocytes from clinical biopsies or ex-
planted human hearts, have been deployed successfully as
in vitro models of hereditary heart disorders (Birket et al.,
2015; Hinson et al., 2015; Moretti et al., 2010; Yazawa et al.,
2011), have predictive power regarding arrhythmic susceptibility
(Gintant et al., 2017), and have begun to yield insights into cell
death in drug-induced and hereditary cardiomyopathies (Bur-
ridge et al., 2016; Cameron et al., 2013; Lee et al., 2017b; Liang
Figure 1. Target Validation for MAP4K4 by Gene Silencing in Human Stem Cell-Derived Cardiomyocytes
(A) Prevalence of the indicated cardiomyocyte markers, by immunostaining, ranged from 80% to 90%. iCell cardiomyocytes were used here and in subsequent
panels. Scale bars, 20 mm.
(B) MAP4K4 protein expression in hiPSC-CMs by immunoprecipitation then western blotting. Untransfected andMAP4K4-transduced HEK293T cells are shown
for comparison.
(C) Potency of theMAP4K4 shRNAs in hiPSC-CMs by qPCR. n = 2 independent experiments, 3 replicates in each; *p% 0.05. Specificity of theMAP4K4 shRNAs
is shown by lack of effect on the two closest MAP4Ks, TNIK and MINK. I, II, and III in (C) and (E) denote V2LHS 68219, V2LHS 202781, and V2LHS 201856.
(D and E) Protection of hiPSC-CMs from 250 mM H2O2 assessed as DRAQ7 uptake in successfully transduced (GFP
+) cardiomyocytes (Myh6-RFP+).
(D) Representative images from the high-content assay for the channels shown. Phenotypes are highlighted for three complementary indicative cells. Circle,
myocyte; triangle, non-myocyte; solid line, live; dotted line, dead. Scale bars, 20 mm.
(E) Protection by the two potent shRNAs shown in (C). n = 2 independent experiments, 6 replicates in each; *p% 0.05.
Results in (C) and (E) are shown as the mean ± SE.
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2017). For this constellation of reasons, hiPSC-CMs are envi-
sioned as a highly auspicious tool for cardiac drug discovery
(Devalla et al., 2015; Gintant et al., 2017; Kirby et al., 2018;
Matsa et al., 2014). Their potential, however, has largely been
unheeded for drug creation in ischemic heart disease, the
most prevalent of all cardiac disorders (GBD 2016 Causes of
Death Collaborators, 2017; GBD 2016 DALYs and HALE Collab-
orators, 2017). We chose to test MAP4K4 function in this clinical
context, using well-characterized, purified, commercially avail-
able hiPSC-CMs that have gained acceptance by industry and
regulatory authorities as highly indicative of drug safety in hu-
mans (Blinova et al., 2018; Gintant et al., 2017; Magdy et al.,
2018; Sala et al., 2017).
First, the prevalence of cardiomyocyte-specific markers and
presence of MAP4K4 protein were validated in iCell cardiomyo-
cytes (Ma et al., 2011; Figures 1A and 1B). Two of three shRNAs
directed against human MAP4K4 reduced expression >60%,
with no extraneous effect on MINK1/MAP4K6 and TNIK/
MAP4K7, the most closely related genes (Figure 1C). Cell death
was quantified by high-content analysis as the loss of membrane
integrity (DRAQ7 uptake) in successfully transduced (GFP+)hiPSC-CMs (Myh6-RFP+; Figure 1D). In this four-channel assay,
roughly 85% of cells were RFP+, half were GFP+ as well, and
death was induced in half the control myocytes. Hence, the spe-
cifically relevant cells in which cardiomyocyte death occurred
were a large sub-population, comprising roughly 20% of the cul-
ture. Each of the two most potent shRNAs conferred protection
against H2O2: cardiomyocyte loss was reduced up to 50% (Fig-
ure 1E). By contrast, shRNA with little effect on MAP4K4 did not
confer protection. Thus, the results of gene silencing strongly
suggest a requirement for endogenous MAP4K4 in human
cardiac muscle cell death.
Pharmacological Inhibition of MAP4K4 Suppresses
Human Cardiac Muscle Cell Death
Based on this portfolio of results—ranging from human to rodent
and back—we postulated that suppressing MAP4K4 pharmaco-
logically would reproduce the benefit achieved by gene silencing
and, consequently, promote human cardiac muscle cell survival.
Therefore, we sought to identify novel small-molecule inhibitors
with sufficient potency and selectivity for further development
toward clinical application. A three-step approach was under-
taken: (1) empirical screening against human MAP4K4, usingCell Stem Cell 24, 1–13, April 4, 2019 3
Figure 2. Selective Small-Molecule Inhibi-
tors of MAP4K4 Created by Field-Point
Modeling and Screening In Silico
(A) Distribution histogram, showing the primary
cell-free screen for inhibitors of human MAP4K4.
(B) Chemical structures of top compounds from
the primary screen, used for the pharmacophore
template (Kenpaullone; GW5074; PD-407824),
subsequent virtual screen (F1386-0303), and me-
dicinal chemistry refinement (DMX-5804).
(C) Dose-response relations for the compounds
in (B), against recombinant human MAP4K4. IC50
values were as follows: Kenpaullone, 30 nM;
GW5074, 30 nM; PD-407824, 1.5 nM; F1386-030,
34 nM; and DMX-5804, 3 nM.
(D) Selectivity profile at 1 mM, shown as a heatmap
of residual activity for 141 human kinases in the
presence of the indicated compounds. Highlighted
at the right for comparison are the few off-target
kinases affected by DMX-5804 at this concentra-
tion (%30% activity). Red, 0%; black, 50%; green,
100%; gray, not tested.
(E) More extensive selectivity profile of DMX-5804
(376 kinases), at 303 its IC50 against MAP4K4.
Results are shown as the mean ± SE.
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field-based similarity analysis of the top primary hits, using the
consensus pharmacophore as seed for a ligand-based virtual
screen (Cheeseright et al., 2011), followed by substructure and
similarity searches (Figure 2B); and (3) refinement of the resulting
tool compound, F1386-0303 (5,7-diphenyl-7H-pyrrolo[2,3-d]
pyrimidin-4-ol), by rational drug design (Figure 2B). Chemical
structures are shown in Figure 2B and full dose-response data
in Figure 2C. Compared to the promiscuity of primary hits,
F1386-0303 was far more selective (25–70 off-target effects
reduced to 5, among 141 human kinases: Figure 2D and Table
S2), with equivalent potency directed solely against the closest
relatives, MINK1 and TNIK (Table 1).
To assess whether the compound traverses the cell mem-
brane and inhibits endogenous MAP4K4, activity in HEK293T
cells was assessed 1 h after treatment at 10 mM. F1386-0303 in-
hibited endogenous MAP4K4 activity by 70% (Figure S4E). In rat
ventricular myocytes, cell death induced by H2O2 was inhibited
50% at this concentration (Figure S4F), equaling the protection
conferred byMap4k4 shRNA (Figures S4C and S4D). No adverse
effect of F1386-0303 was detected at any of the concentrations,4 Cell Stem Cell 24, 1–13, April 4, 2019and rat cardiomyocyte death was in-
hibited by the compound even at 1 mM.
To substantiate these benefits in a
humanmilieu, cytoprotection was next as-
sessed using hiPSC-CMs. Pharmacolog-
ical inhibition by F1386-0303 was highly
protective, suppressing human cardiac
muscle cell death in iCell cardiomyo-
cytes even at micromolar concentrations
(DRAQ7 uptake; Figure S5A), equaling the
benefit achievedbygenesilencing.Human
cardiac muscle cell protection was sub-
stantiated in a second line, vCor.4U cardi-omyocytes, which was likewise validated as physiologically
predictive (Blinova et al., 2018; El-Haou et al., 2018) but is more
highly enriched for ventricular myocytes—the clinically relevant
subtype. The ventricle-specific protein MLC2V was readily de-
tected in >80% of vCor.4U cardiomyocytes (Figure S5B) but just
a minority of iCell cardiomyocytes (Kattman et al., 2011). As com-
plementary forms of oxidative stress, vCor.4U cells were treated
with increasing concentrations of H2O2 or of menadione (vitamin
K3), which induces intracellular reactive oxygen species through
quinone redox cycling (Badave et al., 2016). At 10 mM F1386-
0303, protection from either death signal was virtually complete
(CellTiter-Glo, Figure 3A; human cardiac troponin release, Fig-
ure 3B), even at the highest concentrations used (200 mM H2O2
or 45 mM menadione). Thus, F1386-0303 is a potent, selective
MAP4K4 inhibitor that successfully protects human stem cell-
derived ventricular cardiomyocytes from lethal oxidative stress.
An Enhanced MAP4K4 Inhibitor Rescues Human Stem
Cell-Derived Cardiomyocyte Viability and Function
F1386-0303 does not, however, have sufficient bioavailability
in mice to be used for proof-of-concept studies in vivo: it is











MAP4K4 7.46 8.55 –
MINK1/MAP4K6 7.42 8.18 –
TNIK/MAP4K7 7.03 7.96 –
GCK/MAP4K2 5.91 (35) 6.50 (112) 3.20
GLK/MAP4K3 4.52 (871) 4.95 (3981) 4.57
KHS/MAP4K5 5.22 (174) 6.36 (153) 0.88
ABL1 4.52 (865) 5.80 (560) 0.65
Aurora B 4.88 (380) 5.49 (560) 1.47
FLT3 5.66 (63) 5.31 (1148) 18.22
GSK3b 4.57 (776) 4.66 (7762) 10.00
MLK1/MAP3K9 6.28 (15) 7.19 (23) 1.53
MLK3/MAP3K11 6.09 (23) 6.99 (36) 1.57
NUAK 6.16 (20) 6.88 (47) 2.35
VEGFR 5.72 (55) 5.72 (675) 12.27
Pharmacokinetics
Target F1386-0303 DMX-5804 DMX-5804
versus
F1386-0303
IV PK (1 mg kg–1)
Cl (L hr1 kg1) 5.33 2.50 0.47
t1/2 (h) 0.1 0.6 6.00
Cmax (nM) 3262 1590 0.49
Vd (L kg
1) 1.05 1.22 1.16
Oral PK (50 mg kg–1)
AUCinf 2162 63733 29.48
Cmax (nM) 295 13847 46.94
Tmax (h) 1.00 1.00 1.00
t1/2 (h) 3.7 1.8 0.49
Selectivity: the top compound from pharmacophore modeling (F1386-
0303) and its derivative DMX-5804 were tested for activity against
MAP4K4 and selected other human protein kinases (HTRF Transcreener
ADP assay). Apart from related MAP4Ks, the kinases tested for full dose-
response relations were chosen on the basis of off-target activity in the
Dundee selectivity panel (Table S2). VEGFRwas detected as an off-target
hit of DMX-5804 at the dose used for compound screening, but is nearly
700-fold less sensitive than MAP4K4. Pharmacokinetics: plasma con-
centrations were determined after intravenous or oral administration
at the doses shown. AUCinf, area under the plasma concentration-
time curve from time 0 to infinite; Cl, clearance; Cmax, peak concentration;
t1/2, plasma half-life; Tmax, time of peak concentration; Vd, volume of
distribution.
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dosed orally in mice (Table 1). Analogues of F1386-0303
were therefore created to improve these properties. Notable
among these was 5-[4-(2-methoxy-ethoxy)-phenyl]-7-phenyl-
3,7-dihydro- pyrrolo[2,3-d]pyrimidin-4-one, designated DMX-
5804 (Figure 2B), which was more potent (Figure 2C), selective
(Figures 2D and 2E; Tables 1 and S2), stable in vivo (Table 1),and taken forward for systematic testing in the human
cardiomyocytes.
First, protection was substantiated at 10 mM using vCor.4U
cells as above (Figures 3A and 3B). Across a series of experi-
ments with DMX-5804, the effective concentration that gives a
half-maximal response (EC50) was 500 nM for cell death induced
by 400 mM H2O2, though contingent on the level of stress (Fig-
ure 3C), time of administration (Figure 3D), and specific human
cardiomyocyte line of the three tested (Figure S5C). Of transla-
tional significance, partial protection was seen, even if given
1 h after oxidative stress. Although these complementary lines
differ in their human donor, tissue source, reprogramming vec-
tors, pluripotency genes, methods of differentiation, andmainte-
nance media (Burridge et al., 2014; Ma et al., 2011; Yu et al.,
2007), all three showed the same level of maximal protection.
In vCor.4U cells, this dose response was shifted toward higher
concentrations of compound, which may reflect greater vulnera-
bility of ventricularmyocytes to this form of stress ormerely tech-
nical differences across the lines.
Notably, human cardiomyocyte survival also was promoted in
this model by a beta-adrenergic blocker, metoprolol, that re-
duces infarct size in humans (Ibanez et al., 2013), but not by
inhibition of p38 (Figure 3E), a pathway that failed to show impor-
tance in human trials despite credible large-mammal evidence
(Barancik et al., 2000; Newby et al., 2014). This dichotomy,
although retrospective, suggests the predictive power of
hiPSC-CMs, over standard animal models alone, in prioritizing
targets for reducing human infarct size. Under these conditions,
inhibition of the MAP4K4 target TAK1 (MAP3K7) likewise was
effective.
Compared with F1386-0303, DMX-5804 showed 10-fold
greater potency not only in suppressing recombinant MAP4K4
activity (inhibitor concentration that gives 50% inhibition [IC50],
3 versus 34 nM; Figure 2C) but also in protecting hiPSC-CMs
(EC50 in iCell cardiomyocytes, 0.5 mM versus 5 mM; Fig-
ure 3F). This strict correspondence between cytoprotection
and MAP4K4 inhibition was seen further using two other deriva-
tives of F1386-0303, whose potency in both settings is dimin-
ished at least 10-fold (Figure 3F).
Protection of human cardiomyocyte survival by DMX-5804
also was confirmed using hypoxia-reoxygenation (Figure S5D),
an alternative surrogate for ischemia-reperfusion in vivo.
However, the hiPSC-CMs were less sensitive to hypoxia-reoxy-
genation than to other death signals tested, in agreement with
resistance reported by others (Chen and Vunjak-Novakovic,
2018; Hidalgo et al., 2018).
Given its potency, selectivity, and cytoprotective effects,
DMX-5804 next was investigated for its ability to preserve key
aspects of human cardiomyocyte function after oxidative stress
(Figure 4). Calcium cycling, a hallmark of the cardiac phenotype,
is susceptible to redox- and phosphorylation-dependent abnor-
malities (Meissner, 2017). To determine whether MAP4K4 inhibi-
tion might preserve calcium homeostasis, vCor.4U hiPSC-CMs
were assessed using menadione plus an intracellular calcium in-
dicator (EarlyTox Cardiotoxicity Dye; Molecular Devices; Figures
4A–4C). Calcium cycling was sensitive to oxidative stress even at
sub-lethal concentrations of menadione, with half-maximal loss
of peak area and peak height at 16 mM, at which no confounding
effect on cell viability is observed. The concentration at whichCell Stem Cell 24, 1–13, April 4, 2019 5
Figure 3. Protection of Human Stem Cell-
Derived Ventricular Myocytes by Small-
Molecule Inhibitors of MAP4K4
(A and B) vCor.4U ventricular myocytes were as-
sayed 24 h after oxidative stress conferred byH2O2
(left) or menadione (right) at the indicated
concentrations, ±DMX-5804 or the parent com-
pound F1386-0303 (10 mM) 1 h prior to insult.
Cardiomyocyte protection was confirmed in three
independent experiments, using three different
lots of vCor.4U cells (CV98CL V, CV99CL V,
and CV102CL V). A representative dose-response
curve is shown in each panel (2 replicate wells per
condition).
(A) CellTiter-Glo assay. Results (% viability) are
normalized to the difference between untreated
control cells (no death signal and no inhibitor)
versus 100% cell death (0.1% Triton X-100 2 h
before CellTiter-Glo [CTG]).
(B) Human cardiac troponin I release (AlphaLISA).
(C) Cross-titration of DMX-5804 and H2O2. (Left)
CellTiter Glo is shown; (right) troponin release is
shown; n = 10. Arrows illustrate the loss of viability
at 500 mM H2O2 and rescue by 10 mM DMX-5804.
The half-maximal concentration for protection
shifts systematically rightward as oxidative stress
increases. To minimize inter-experimental varia-
tion, results at a fixed concentration of death signal
(D–F: CellTiter Glo;% rescue) are normalized to the
difference between untreated control cells versus
stress-induced death in the absence of inhibitor.
(D) Partial protection by MAP4K4 inhibitors given
1 h before versus 1 h after 400 mM H2O2; NR 3.
(E) vCor.4U cells were stressed with 400 mM H2O2
1 h after treatment with the compounds shown.
Nine-point dose-response curves were obtained;
for clarity, rescue of viability is shown as a bar
graph at the highest concentration (10 mM). Fidelity
to pathways driving infarct size in human trials is
suggested by the positive result for b1-adrenergic
blockade and weak result for p38. Inhibition
of the MAP4K4 target TAK1 was likewise effec-
tive; NR 3; *p = 0.0225; **p = 0.0011.
(F) (Left) Dose-response relations for in-cell activ-
ity, measured as protection from 400 mM H2O2
(CellTiter-Glo). (Right) Potency for human car-
diomyocyte protection correlates with the potency
against recombinant human MAP4K4, across
three orders of magnitude.
Results are shown as the mean ± SE.
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0.5–2 mM, and varied with the level of dysfunction conferred by
menadione in each experiment. Protection was maintained for
up to 96 h, despite the presence of menadione throughout.
Similar to its greater effects both in vitro and in cell survival (Fig-
ures 2C and 3F), DMX-5804 was 5- to 10-fold more potent than
F1386-0303 in protecting calcium cycling under the sub-lethal
conditions tested (Figure S5E). Although the tested protocol
for hypoxia-reoxygenation provoked less than 20% cell death,
spontaneous calcium cycling was markedly inhibited, and pro-
tection was conferred by DMX-5804 (Figure S5F).
Maximum oxidative capacity, a measure of mitochondrial
respiration, was reduced to 15% of control levels by menadione
(15 mM; 2 h), and residual activity was improved 5-fold by 10 mM6 Cell Stem Cell 24, 1–13, April 4, 2019DMX-5804 (Figure 4D, left). No significant benefits in this param-
eter were seen at lesser concentrations. Likewise, 10 mM
DMX-5804 partially rescued the extracellular acidification rate,
a measure of glycolytic function (Figure 4D, right).
Next, protection was assessed in vCor.4U cells configured as
3D human-engineered heart tissue (hEHT), a model in which the
maturity of physiological properties is further enhanced (Hansen
et al., 2010; Lemoine et al., 2017; Weinberger et al., 2017). Cell
death from menadione was greatest in the first 24 h after treat-
ment and suppressed by 10 mM DMX-5804 (Figure 4E). Sponta-
neous beating and, hence, force generation were decreased by
menadione within 60min and were abolished at 24 h. The rescue
of contractile function by 3 or 10 mM DMX-5804 was virtually
complete at these time points, although not later ones.
Figure 4. MAP4K4 Inhibition Rescues Mitochondrial Function, Calcium Cycling, and Contractile Function in Human Ventricular Myocytes
(A–C) Calcium oscillations in vCor.4U cells. Protection was confirmed in three independent experiments; one representative set of dose-response curves is
shown (4 replicate wells for each condition).
(A) Spontaneous calcium transients at 24 h were suppressed by menadione even at sub-lethal concentrations (CellTiter-Glo assay).
(B) Rescue by DMX-5804.
(C) Representative calcium transients. (Left) DMX-5804 had no effect on baseline calcium cycling. (Right) Preservation of calcium cycling by DMX-5804 in
menadione-treated cells is shown.
(legend continued on next page)
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adverse effect of DMX-5804 was seen in 2D culture or hEHT
on any of the parameters tested—cardiomyocyte viability, rhyth-
micity, calcium handling, mitochondrial function, and force gen-
eration. Likewise, no off-target effect was seen in cloned human
ion channels (hERG, hNaV1.5, and hCaV1.2: Figure S5G), Ames
test of mutagenic potential, glutathione (GSH)-trapping, or
Cerep Safety 44 panel, except metallothionein 3.
MAP4K4 Inhibition Reduces Infarct Size in Mice
To test whether MAP4K4 target validation and compound devel-
opment in hiPSC-CMs might predict success in a whole-animal
context, mice undergoing experimental myocardial infarction
were treated with DMX-5804 or the vehicle control (Figure 5).
As a result of its reduced clearance, the free plasma concentra-
tions of DMX-5804 were 334 and 8 nM, respectively, 1 and 10 h
after a 50 mg kg1 oral dose, showing more than 80-fold
improvement over the initial inhibitor tested (Figure 5A; Table
S4). Target engagement measured ex vivo, as a block to desthio-
biotin-ATP binding (Patricelli et al., 2011), demonstrated 103
greater affinity for DMX-5804 over the earlier compound in adult
mouse cardiac lysates (Figure 5B). To provide direct proof of
target engagement in vivo, cardiac lysates after oral dosing
were incubated with the covalent ATP probe, and MAP4K4
was immunoprecipitated for dose-response and time course
studies (Figures 5C and 5D). The inhibition of ATP binding to car-
diac MAP4K4 was substantiated for DMX-5804 given in vivo and
corresponded well to tissue levels of the compound. Based on
these pharmacokinetic and pharmacodynamic results, mice
received 50 mg kg1 twice by gavage, spaced 10 h apart, to
achieve coverage for nearly a day exceeding the measured
EC50 for cardiomyocyte protection (Figure 5E). Treatment was
begun either 20 min prior to ischemia or 1 h after reperfusion
injury, the latter having greater relevance to potential clinical
benefits. Suppression of total cardiac muscle cell death by
more than half was achieved in both studies, reducing infarct
size as a proportion of the area at ischemic risk (pre-injury:
48.5% versus 20.9%; post-injury: 55.1% versus 25.6%; Fig-
ure 5F). As an independent and selective measurement of cell
death, TUNEL staining was performed in the post-injury study,
demonstrating suppression of cardiomyocyte apoptosis within
the infarct itself and adjacent jeopardized myocardium by 39%
and 52%, respectively (Figure 5G). Given the known large contri-
butions of both apoptosis and necrosis to infarct size (Whelan
et al., 2010), the net effect we demonstrated cannot be recon-
ciled with just a partial block to apoptosis alone.
DISCUSSION
A scientific case for MAP4K4 is suggested bymany conventional
criteria (‘‘observational’’ biochemistry, mouse models, and ro-(D) Mitochondrial function was assessed in vCor.4U cells using menadione as t
Mitochondrial respiration (left) and glycolysis (center) were suppressed by menad
versus menadione; **p% 0.01 versus menadione. p values (right) denote treatm
(E) vCor.4U cells were cultured as 3D engineered heart tissue and subjected to me
*p < 0.001 versus menadione; **p = 0.02 versus menadione. (Center) Preservation
**p% 0.03 versus menadione. (Right) Preservation of force generation is shown.
Results are shown as the mean ± SE.
8 Cell Stem Cell 24, 1–13, April 4, 2019dent cardiomyocytes), although these, even taken together,
are merely tentative or provisional indications of a functional
role in humans. This standard pipeline for cardiac drug discov-
ery—‘‘flying blind’’ with respect to human efficacy—is notori-
ously failure prone (Fordyce et al., 2015; Gromo et al., 2014),
prompting academic and industry-based investigators alike to
embrace target validation in human cardiomyocytes from plurip-
otent stem cells as an accessible, scalable, transformative alter-
native (Bellin et al., 2012; Burridge et al., 2016; Cameron et al.,
2013; Gintant et al., 2017; Lee et al., 2017b; Liang et al., 2013;
Mathur et al., 2015; Matsa et al., 2014, 2016; Sharma et al.,
2017). Here, using hiPSC-CMs as the most relevant platform
for gene silencing and drug discovery, we created small-mole-
cule inhibitors of MAP4K4 through field-point modeling and
screening in silico. F1386-0303 mimics the protective effect of
MAP4K4 shRNA in the human cardiomyocytes. A further drug
discovery endeavor led from this initial tool compound to one
suitable for in vivo studies, DMX-5804, enhanced ten-fold for po-
tency both against the recombinant human kinase and against
cell death in human cardiac muscle cells. Whereas the earlier
compound was unsuited to whole-animal testing on the grounds
of rapid clearance and poor bioavailability, DMX-5804 success-
fully reduced infarct size in mice, even given 1 h after reperfusion
injury. The solubility and pharmacokinetic properties of DMX-
5804 itself remain insufficient for a human drug candidate in
acute ischemic injury, where rapid intravenous infusion is
desired. However, this chemical series yielded useful tool com-
pounds that enabled us to conduct rigorous validation in human
cardiomyocytes, taken forward successfully into proof-of-
concept studies in vivo. On this basis, we propose that pharma-
cological inhibition of MAP4K4 is a conceptually sound target
for further development toward rational cardioprotection in
the clinic, taking intravenous analogs forward into the requisite
studies of toxicity, long-term efficacy, and large-mammal
effects.
An agent that suppresses human cardiac muscle cell death is
expected to provide additional benefit beyond current therapies,
and our data suggest that inhibiting MAP4K4 might be a worth-
while approach to accomplish this. H2O2- or menadione-
induced oxidative stress—the trigger of cell death tested
here—replicates key features of both acute and chronic heart
disease (Brown and Griendling, 2015). Though the molecular
events driving MAP4K4 activation by oxidative stress are not
yet known, the a priori possibilities include receptor-mediated
signals, activation of an upstream signaling protein like RAP2
(Meng et al., 2018) or PYK (Loftus et al., 2013), or direct biochem-
ical activation by caspase cleavage (Chang et al., 2006) or redox
sensing (Burgoyne et al., 2007; Guo et al., 2010; Nadeau et al.,
2009). Interestingly, effectors of MAP4K4 have been proposed
as therapeutic targets in cardiovascular disease and neuronal
injury: at least in preclinical studies, inhibiting TAK1/MAP3K7 ishe oxidative stress (15 mM; 2 h), followed by the sequential inhibitors shown.
ione and rescued by 10 mM DMX-5804. For pairwise comparisons, *p < 0.001
ent effects calculated as area under the curve (AUC).
nadione for 24 h ± DMX-5804. (Left) Suppression of cell death at 24 h is shown.
of spontaneous beating at 1 and 24 h is shown. *p < 0.001 versus menadione;
*p < 0.001 versus menadione; **p = 0.008 versus menadione.
Figure 5. MAP4K4 Inhibition Reduces Infarct Size in Mice
(A) Plasma concentrations of DMX-5804 versus F1386-0303 in mice, after oral doses of 50 mg kg1. Whereas F1386-0303 levels were 10-fold less than the
compound’s EC50 (black), sufficient in vivo coverage was achieved with DMX-5804 (red). Using a second dose at 10 h, levels exceeded the EC50 for nearly 1 day.
(B–D) Target engagement, shown as a block to desthiobiotin-ATP binding by cardiac MAP4K4 ± the ATP-competitive inhibitors.
(B) Target engagement ex vivo, in adult mouse cardiac lysates, demonstrates 103 greater affinity for DMX-5804.
(C and D) Target engagement in vivo, shown for (C) dose response and (D) time course. Cardiac levels of DMX-5804 (above) conformed to the time course for
plasma concentrations and reciprocal with the levels of ATP binding to cardiac MAP4K4 (below).
(E) Schematic representation of the pre- and post-injury treatment protocols (not to scale). Mice were given the first dose of DMX-5804 20min before the onset of
ischemia (above) or 1 h after reperfusion was initiated (below). Black, ischemia; red and light red, intervals of coverage by the first and second dose, respectively.
Dosing was chosen to exceed the compound’s EC50 for 20 h (Figure 2E).
(legend continued on next page)
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blocking MAP4K4 along with TNIK and MINK (our principal off-
target effects) is beneficial in neurodegeneration (Larhammar
et al., 2017).
Numerous logical targets to enhance cardiac muscle cell sur-
vival have failed in human studies, but all thus far, without excep-
tion, were taken forward on the basis of non-human models
alone (Hausenloy and Yellon, 2015; Heusch, 2013; Lincoff
et al., 2014; Newby et al., 2014; Piot et al., 2008). Of even
more general importance, therefore, our studies reinforce the
utility of human stem cell-derived cardiomyocytes, not solely
for safety pharmacology and patient-specificmodels of inherited
cardiac disorders, but also toward target discovery and drug
development in acute myocardial infarction, a pandemic form
of acquired heart disease. Suggesting the fidelity and potential
predictive power of this model, the extent of protection
conferred by inhibiting MAP4K4 was equal to that achieved
with beta1-adrenergic blockade (one of the very few pathways
that succeeded in the clinic) and far surpassed that with inhibi-
tion of p38 (a pathway that did not; Ibanez et al., 2013; Newby
et al., 2014). We suggest this dichotomy lends credence to the
cells’ use to help prioritize among the myriad of possible targets
in cardiac muscle cell death, acting in series or in parallel with
MAP4K4.
Moreover, beyond its central and indispensable role toward
helping ensure target validity, our use of human stem cell deriv-
atives provided immediate evidence of safety in the human car-
diac context (no cytotoxicity, arrhythmia, disturbance of calcium
cycling, or impaired force generation), as well as pinpointing the
required concentrations to inform human dosing. It will be
intriguing in future studies to determine which exact substrates
and pathways are the responsible mediators of MAP4K4 in hu-
man cardiomyocytes, to define the mechanism(s) of MAP4K4
activation, and ultimately to identify the acute and chronic hu-
man cardiac disorders in which MAP4K4 inhibition might be
most beneficial. An acknowledged limitation of hiPSC-CMs
and other reductionist systems by comparison to the native adult
organ is incomplete recapitulation of in vivo biology, attributable
to functional immaturity and the lack of key cell-cell interactions.
Offsetting this admitted disadvantage, even 2D cultures of pure
hiPSC-CMs have well-demonstrated predictive power (Burridge
et al., 2016; Devalla et al., 2015; Gintant et al., 2017; Matsa et al.,
2014, 2016), with even higher fidelity attained in the 3D human-
engineered heart tissue we used (Lemoine et al., 2017). Refine-
ments suitable for future work include enhancing metabolic
maturation (Chen and Vunjak-Novakovic, 2018; Hidalgo et al.,
2018) and heart-on-chip models that incorporate multiple cell
types (Lemoine et al., 2017; Ronaldson-Bouchard et al., 2018).
More than 30 mouse models exist that implicate specific protein
kinases in cardiomyocyte death or survival, with no human proof
of function to date (Fiedler et al., 2014). How might one prioritize(F) Infarct size. (Left) Representative tissue sections 24 h after myocardial infarctio
size (white) and area at risk (AAR) is shown. (Below) Image analysis and quantitatio
AAR. NR 5; *p = 0.0021. (Right) Post-injury treatment with DMX-5804 reduces i
(G) Cardiomyocyte apoptosis. (Left) Representative confocal microscopy of card
Myocytes are shown in short-axis orientation. Scale bar, 20 mm. (Right) Post
*p = 0.0014; **p = 0.0028. Representative images (F and G) are taken from the p
Results are shown as the mean ± SE.
10 Cell Stem Cell 24, 1–13, April 4, 2019among these, toward more effective cardiac drug discovery? By
analogy to the instrumental role in drug discovery for human
cancer cell lines (Wilding and Bodmer, 2014), we speculate
that therapeutic targets and interventions that hold true not
merely in animal models but also in human cardiomyocytes
and 3D heart tissue from pluripotent stem cells may be prudent,
well-posed choices for advancement toward human trials of
suppressing cardiac muscle cell death.STAR+METHODS
Detailed methods are provided in the online version of this paper
and include the following:
d KEY RESOURCES TABLE
d CONTACT FOR REAGENT AND RESOURCE SHARING













B Quantitative real-time PCR (qRT-PCR)
B Immune complex kinase assays
B Human cardiac muscle cell death
B Compound treatment
B CellTiter-Glo (CTG) luminescent cell viability assay
B Troponin I detection
B Hypoxia-reoxygenation assay
B Ion channel safety screening
B Ames genotoxicity reverse mutation assay
B In vitro MAP4K4 kinase activity assay
B Computational chemistry
B Selectivity and microsomal stability assays
B Analytical chemistry
B Preparative High Performance Liquid Chromatog-
raphy (HPLC)
B Step 1: 4-Chloro-5-iodo-7-phenyl-7H-pyrrolo[2,3-d]
pyrimidine (3)
B Step 2: 5-Iodo-7-phenyl-3,7-dihydro-pyrrolo[2,3-d]
pyrimidin-4-one (4)
B Step 3: 5-[4-(2-Methoxy-ethoxy)-phenyl]-7-phenyl-
3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one
(DMX0005804)
B Human cardiac muscle cell function
B Human engineered heart tissue
B Oral PK
B Target engagement assaysDMX-5804 are shown. (Above) TTC/Evans blue staining to delineate infarct
e shown. (Center) Pre-injury treatment with DMX-5804 reduces infarct size/
ct size/AAR. NR 5; *p = 0.0015.
yocyte apoptosis 24 h after myocardial infarction ± DMX-5804 is shown.
ry treatment with DMX-5804 reduces cardiomyocyte apoptosis. n = 4;
injury treatment study.
Please cite this article in press as: Fiedler et al., MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces
Infarct Size In Vivo, Cell Stem Cell (2019), https://doi.org/10.1016/j.stem.2019.01.013B Histology
B Rat cardiac muscle cell death
B Adenoviruses
d QUANTIFICATION AND STATISTICAL ANALYSIS
d DATA AND SOFTWARE AVAILABILITY
SUPPLEMENTAL INFORMATION
Supplemental Information can be found with this article online at https://doi.
org/10.1016/j.stem.2019.01.013.
ACKNOWLEDGMENTS
We are grateful to the investigators cited for key reagents; F. al-Beidh,
D. Zhang, X. Wang,W. Boerwinkle, L. Shirley, Q. Xiang, T. Pham, and J. Pocius
for assistance; F. de Mayo and the Baylor College of Medicine Transgenic
Mouse Core; S. Rothery and the Imperial Facility for Imaging by Light Micro-
scopy; D. Alessi and staff of the Medical Research Council (MRC) Protein
Phosphorylation and Ubiquitination Unit; and members of the British Heart
Foundation (BHF) Centre for Research Excellence for discussions. This work
was supported in part by the BHF (CH/08/002/29257, RE/08/002, RG/08/
007, and SI/11/2/28875), European Commission (223372), European
Research Council (233158), MRC-BHF Cardiovascular Stem Cell Research
Strategic Development Grant (G0901467), MRC-Imperial Confidence in
Concept Fund (MC PC 12015), NIH (R01 HL52555), and Wellcome Trust
(WT10638 and WT205256).
AUTHOR CONTRIBUTIONS
Conceptualization, M.D.S.; Methodology, R.A., K.C., D.F., L.R.F., S.E.H., A.J.,
M.J., C.M.R.L., E.M., G.N., D.S., M.S., M.D.S., C.T.-S., D.J.S., and M.X.;
Formal Analysis, K.C., A.J., C.M.R.L., G.N., T.P., and C.T.-S.; Investigation,
M.B., K.C., M.L.E., D.F., L.R.F., P.A.G., M.H., S.E.H., M.J., S.K., E.M.,
L.H.M., M.N., P.N., M.A.P., L.P., R.D.S., D.S., M.D.S., W.S., D.J.S., G.E.T.,
S.C.W., M.X., and R.Y.; Resources, T.-H.T. and M.D.S.; Writing – Original
Draft, K.C., L.R.F., A.J., M.J., T.P., M.D.S., and M.X.; Writing – Review & Edit-
ing, K.C., L.R.F., M.J., G.N., T.P., M.D.S., and M.X.; Supervision, T.P. and
M.D.S.; Project Administration, T.P. and M.D.S.; Funding Acquisition, M.D.S.
DECLARATION OF INTERESTS
M.D.S. declares patent applications related to this work (UK patent applica-
tions nos. 1716867.5 and 1819839.0; international patent application no.
PCT/GB2018/052936).
Received: November 10, 2017
Revised: December 24, 2018
Accepted: January 30, 2019
Published: March 7, 2019
REFERENCES
Badave, K.D., Khan, A.A., and Rane, S.Y. (2016). Anticancer vitamin K3 ana-
logs: a review. Anticancer. Agents Med. Chem. 16, 1017–1030.
Bain, J., Plater, L., Elliott, M., Shpiro, N., Hastie, C.J., McLauchlan, H.,
Klevernic, I., Arthur, J.S., Alessi, D.R., and Cohen, P. (2007). The selectivity
of protein kinase inhibitors: a further update. Biochem. J. 408, 297–315.
Barancik, M., Htun, P., Strohm, C., Kilian, S., and Schaper, W. (2000). Inhibition
of the cardiac p38-MAPK pathway by SB203580 delays ischemic cell death.
J. Cardiovasc. Pharmacol. 35, 474–483.
Bellin, M., Marchetto, M.C., Gage, F.H., and Mummery, C.L. (2012). Induced
pluripotent stem cells: the new patient? Nat. Rev. Mol. Cell Biol. 13, 713–726.
Bertero, E., and Maack, C. (2018). Calcium signaling and reactive oxygen
species in mitochondria. Circ. Res. 122, 1460–1478.
Birket, M.J., Ribeiro, M.C., Kosmidis, G., Ward, D., Leitoguinho, A.R., van de
Pol, V., Dambrot, C., Devalla, H.D., Davis, R.P., Mastroberardino, P.G., et al.
(2015). Contractile defect caused bymutation inMYBPC3 revealed under con-ditions optimized for human PSC-cardiomyocyte function. Cell Rep. 13,
733–745.
Blinova, K., Dang, Q., Millard, D., Smith, G., Pierson, J., Guo, L., Brock, M., Lu,
H.R., Kraushaar, U., Zeng, H., et al. (2018). International multisite study of hu-
man-induced pluripotent stem cell-derived cardiomyocytes for drug proar-
rhythmic potential assessment. Cell Rep. 24, 3582–3592.
Breckwoldt, K., Letuffe-Brenie`re, D., Mannhardt, I., Schulze, T., Ulmer, B.,
Werner, T., Benzin, A., Klampe, B., Reinsch, M.C., Laufer, S., et al. (2017).
Differentiation of cardiomyocytes and generation of human engineered heart
tissue. Nat. Protoc. 12, 1177–1197.
Brown, D.I., and Griendling, K.K. (2015). Regulation of signal transduction
by reactive oxygen species in the cardiovascular system. Circ. Res. 116,
531–549.
Burgoyne, J.R., Madhani, M., Cuello, F., Charles, R.L., Brennan, J.P.,
Schro¨der, E., Browning, D.D., and Eaton, P. (2007). Cysteine redox sensor in
PKGIa enables oxidant-induced activation. Science 317, 1393–1397.
Burridge, P.W., Matsa, E., Shukla, P., Lin, Z.C., Churko, J.M., Ebert, A.D., Lan,
F., Diecke, S., Huber, B., Mordwinkin, N.M., et al. (2014). Chemically defined
generation of human cardiomyocytes. Nat. Methods 11, 855–860.
Burridge, P.W., Li, Y.F., Matsa, E., Wu, H., Ong, S.G., Sharma, A., Holmstro¨m,
A., Chang, A.C., Coronado, M.J., Ebert, A.D., et al. (2016). Human induced
pluripotent stem cell-derived cardiomyocytes recapitulate the predilection of
breast cancer patients to doxorubicin-induced cardiotoxicity. Nat. Med. 22,
547–556.
Cameron, B.J., Gerry, A.B., Dukes, J., Harper, J.V., Kannan, V., Bianchi, F.C.,
Grand, F., Brewer, J.E., Gupta, M., Plesa, G., et al. (2013). Identification of a
Titin-derived HLA-A1-presented peptide as a cross-reactive target for engi-
neered MAGE A3-directed T cells. Sci. Transl. Med. 5, 197ra103.
Chang, J., Xie, M., Shah, V.R., Schneider, M.D., Entman, M.L., Wei, L., and
Schwartz, R.J. (2006). Activation ofRho-associated coiled-coil protein kinase 1
(ROCK-1) by caspase-3 cleavage plays an essential role in cardiac myocyte
apoptosis. Proc. Natl. Acad. Sci. USA 103, 14495–14500.
Chapman, J.O., Li, H., and Lundquist, E.A. (2008). The MIG-15 NIK kinase acts
cell-autonomously in neuroblast polarization and migration in C. elegans. Dev.
Biol. 324, 245–257.
Cheeseright, T.J., Mackey, M.D., and Scoffin, R.A. (2011). High content
pharmacophores from molecular fields: a biologically relevant method for
comparing and understanding ligands. Curr. Comput. Aided Drug Des. 7,
190–205.
Chen, T., and Vunjak-Novakovic, G. (2018). In vitro models of ischemia-reper-
fusion injury. Regen. Eng. Transl. Med. 4, 142–153.
Chen, S., Li, X., Lu, D., Xu, Y., Mou, W., Wang, L., Chen, Y., Liu, Y., Li, X., Li,
L.Y., et al. (2014). SOX2 regulates apoptosis through MAP4K4-survivin
signaling pathway in human lung cancer cells. Carcinogenesis 35, 613–623.
Dan, I., Watanabe, N.M., and Kusumi, A. (2001). The Ste20 group kinases as
regulators of MAP kinase cascades. Trends Cell Biol. 11, 220–230.
Devalla, H.D., Schwach, V., Ford, J.W., Milnes, J.T., El-Haou, S., Jackson, C.,
Gkatzis, K., Elliott, D.A., Chuva de Sousa Lopes, S.M., Mummery, C.L., et al.
(2015). Atrial-like cardiomyocytes from human pluripotent stem cells are a
robust preclinical model for assessing atrial-selective pharmacology. EMBO
Mol. Med. 7, 394–410.
Dorn, G.W., 2nd (2009). Novel pharmacotherapies to abrogate postinfarction
ventricular remodeling. Nat. Rev. Cardiol. 6, 283–291.
El-Haou, S., Williams, S., Webdale, L., Rogers, M., and Sutton, K. (2018).
Comprehensive profiling of axiogenesis ventricular vCor.4U iPSC-derived
cardiomyocytes—from electrophysiology to phenotypic assays. J. Pharm.
Tox. Methods 93, 167–168.
Fiedler, L.R., Maifoshie, E., and Schneider, M.D. (2014). Mouse models of
heart failure: cell signaling and cell survival. Curr. Top. Dev. Biol. 109, 171–247.
Fordyce, C.B., Roe, M.T., Ahmad, T., Libby, P., Borer, J.S., Hiatt, W.R.,
Bristow, M.R., Packer, M., Wasserman, S.M., Braunstein, N., et al. (2015).
Cardiovascular drug development: is it dead or just hibernating? J. Am. Coll.
Cardiol. 65, 1567–1582.Cell Stem Cell 24, 1–13, April 4, 2019 11
Please cite this article in press as: Fiedler et al., MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces
Infarct Size In Vivo, Cell Stem Cell (2019), https://doi.org/10.1016/j.stem.2019.01.013Gao, X.M., Xu, Q., Kiriazis, H., Dart, A.M., and Du, X.J. (2005). Mouse model of
post-infarct ventricular rupture: time course, strain- and gender-dependency,
tensile strength, and histopathology. Cardiovasc. Res. 65, 469–477.
GBD 2016 Causes of Death Collaborators (2017). Global, regional, and na-
tional age-sex specific mortality for 264 causes of death, 1980-2016: a sys-
tematic analysis for the Global Burden of Disease Study 2016. Lancet 390,
1151–1210.
GBD 2016 DALYs and HALE Collaborators (2017). Global, regional, and na-
tional disability-adjusted life-years (DALYs) for 333 diseases and injuries and
healthy life expectancy (HALE) for 195 countries and territories, 1990-2016:
a systematic analysis for the Global Burden of Disease Study 2016. Lancet
390, 1260–1344.
Gintant, G., Fermini, B., Stockbridge, N., and Strauss, D. (2017). The evolving
roles of human iPSC-derived cardiomyocytes in drug safety and discovery.
Cell Stem Cell 21, 14–17.
Gromo, G., Mann, J., and Fitzgerald, J.D. (2014). Cardiovascular drug discov-
ery: a perspective from a research-based pharmaceutical company. Cold
Spring Harb. Perspect. Med. 4, a014092.
Guo, Z., Kozlov, S., Lavin, M.F., Person, M.D., and Paull, T.T. (2010). ATM acti-
vation by oxidative stress. Science 330, 517–521.
Hansen, A., Eder, A., Bo¨nstrup, M., Flato, M., Mewe, M., Schaaf, S.,
Aksehirlioglu, B., Schwoerer, A.P., Uebeler, J., and Eschenhagen, T. (2010).
Development of a drug screening platform based on engineered heart tissue.
Circ. Res. 107, 35–44.
Hausenloy, D.J., and Yellon, D.M. (2015). Targeting myocardial reperfusion
injury–the search continues. N. Engl. J. Med. 373, 1073–1075.
Heusch, G. (2013). Cardioprotection: chances and challenges of its translation
to the clinic. Lancet 381, 166–175.
Hidalgo, A., Glass, N., Ovchinnikov, D., Yang, S.-K., Zhang, X., Mazzone, S.,
Chen, C., Wolvetang, E., and Cooper-White, J. (2018). Modelling ischemia-
reperfusion injury (IRI) in vitro using metabolically matured induced pluripotent
stem cell-derived cardiomyocytes. APL Bioeng. 2, 026102.
Hinson, J.T., Chopra, A., Nafissi, N., Polacheck, W.J., Benson, C.C., Swist, S.,
Gorham, J., Yang, L., Schafer, S., Sheng, C.C., et al. (2015). HEART DISEASE.
Titin mutations in iPS cells define sarcomere insufficiency as a cause of dilated
cardiomyopathy. Science 349, 982–986.
Ibanez, B., Macaya, C., Sa´nchez-Brunete, V., Pizarro, G., Ferna´ndez-Friera, L.,
Mateos, A., Ferna´ndez-Ortiz, A., Garcı´a-Ruiz, J.M., Garcı´a-A´lvarez, A.,
In˜iguez, A., et al. (2013). Effect of early metoprolol on infarct size in
ST-segment-elevation myocardial infarction patients undergoing primary
percutaneous coronary intervention: the effect of metoprolol in cardioprotec-
tion during an acute myocardial infarction (METOCARD-CNIC) trial. Circulation
128, 1495–1503.
Jacquet, S., Nishino, Y., Kumphune, S., Sicard, P., Clark, J.E., Kobayashi,
K.S., Flavell, R.A., Eickhoff, J., Cotten, M., and Marber, M.S. (2008). The role
of RIP2 in p38 MAPK activation in the stressed heart. J. Biol. Chem. 283,
11964–11971.
Kattman, S.J., Koonce, C.H., Swanson, B.J., and Anson, B.D. (2011). Stem
cells and their derivatives: a renaissance in cardiovascular translational
research. J. Cardiovasc. Transl. Res. 4, 66–72.
Kirby, R.J., Divlianska, D.B., Whig, K., Bryan, N., Morfa, C.J., Koo, A., Nguyen,
K.H., Maloney, P., Peddibhotla, S., Sessions, E.H., et al. (2018). Discovery of
novel small-molecule inducers of heme oxygenase-1 that protect human
iPSC-derived cardiomyocytes from oxidative stress. J. Pharmacol. Exp.
Ther. 364, 87–96.
Larhammar, M., Huntwork-Rodriguez, S., Rudhard, Y., Sengupta-Ghosh, A.,
and Lewcock, J.W. (2017). The Ste20 family kinases MAP4K4, MINK1, and
TNIK converge to regulate stress-induced JNK signaling in neurons.
J. Neurosci. 37, 11074–11084.
Lee, S.H., Cunha, D., Piermarocchi, C., Paternostro, G., Pinkerton, A.,
Ladriere, L., Marchetti, P., Eizirik, D.L., Cnop, M., and Levine, F. (2017a).
High-throughput screening and bioinformatic analysis to ascertain com-
pounds that prevent saturated fatty acid-induced b-cell apoptosis. Biochem.
Pharmacol. 138, 140–149.12 Cell Stem Cell 24, 1–13, April 4, 2019Lee, Y.K., Lau, Y.M., Cai, Z.J., Lai, W.H., Wong, L.Y., Tse, H.F., Ng, K.M., and
Siu, C.W. (2017b). Modeling treatment response for Lamin A/C related dilated
cardiomyopathy in human induced pluripotent stem cells. J. Am. Heart Assoc.
6, e005677.
Lemoine, M.D., Mannhardt, I., Breckwoldt, K., Prondzynski, M., Flenner, F.,
Ulmer, B., Hirt, M.N., Neuber, C., Horva´th, A., Kloth, B., et al. (2017). Human
iPSC-derived cardiomyocytes cultured in 3D engineered heart tissue show
physiological upstroke velocity and sodium current density. Sci. Rep. 7, 5464.
Liang, P., Lan, F., Lee, A.S., Gong, T., Sanchez-Freire, V., Wang, Y., Diecke, S.,
Sallam, K., Knowles, J.W., Wang, P.J., et al. (2013). Drug screening using a li-
brary of human induced pluripotent stem cell-derived cardiomyocytes reveals
disease-specific patterns of cardiotoxicity. Circulation 127, 1677–1691.
Lin, B., Li, Y., Han, L., Kaplan, A.D., Ao, Y., Kalra, S., Bett, G.C., Rasmusson,
R.L., Denning, C., and Yang, L. (2015). Modeling and study of the mechanism
of dilated cardiomyopathy using induced pluripotent stem cells derived from
individuals with Duchennemuscular dystrophy. Dis. Model. Mech. 8, 457–466.
Lincoff, A.M., Roe, M., Aylward, P., Galla, J., Rynkiewicz, A., Guetta, V.,
Zelizko, M., Kleiman, N., White, H., McErlean, E., et al.; PROTECTION AMI
Investigators (2014). Inhibition of delta-protein kinase C by delcasertib as an
adjunct to primary percutaneous coronary intervention for acute anterior
ST-segment elevation myocardial infarction: results of the PROTECTION
AMI randomized controlled trial. Eur. Heart J. 35, 2516–2523.
Loftus, J.C., Yang, Z., Kloss, J., Dhruv, H., Tran, N.L., and Riggs, D.L. (2013). A
novel interaction between Pyk2 and MAP4K4 Is integrated with glioma cell
migration. J. Signal Transduct. 2013, 956580.
Ma, J., Guo, L., Fiene, S.J., Anson, B.D., Thomson, J.A., Kamp, T.J., Kolaja,
K.L., Swanson, B.J., and January, C.T. (2011). High purity human-induced
pluripotent stem cell-derived cardiomyocytes: electrophysiological properties
of action potentials and ionic currents. Am. J. Physiol. Heart Circ. Physiol. 301,
H2006–H2017.
Magdy, T., Schuldt, A.J.T., Wu, J.C., Bernstein, D., and Burridge, P.W. (2018).
Human induced pluripotent stem cell (hiPSC)-derived cells to assess drug
cardiotoxicity: opportunities and problems. Annu. Rev. Pharmacol. Toxicol.
58, 83–103.
Mathur, A., Loskill, P., Shao, K., Huebsch, N., Hong, S., Marcus, S.G., Marks,
N., Mandegar, M., Conklin, B.R., Lee, L.P., and Healy, K.E. (2015). Human
iPSC-based cardiac microphysiological system for drug screening applica-
tions. Sci. Rep. 5, 8883.
Matsa, E., Burridge, P.W., andWu, J.C. (2014). Human stem cells for modeling
heart disease and for drug discovery. Sci. Transl. Med. 6, 239ps6.
Matsa, E., Burridge, P.W., Yu, K.H., Ahrens, J.H., Termglinchan, V., Wu, H.,
Liu, C., Shukla, P., Sayed, N., Churko, J.M., et al. (2016). Transcriptome
profiling of patient-specific human iPSC-cardiomyocytes predicts individual
drug safety and efficacy responses in vitro. Cell Stem Cell 19, 311–325.
Meissner, G. (2017). The structural basis of ryanodine receptor ion channel
function. J. Gen. Physiol. 149, 1065–1089.
Meng, Z., Qiu, Y., Lin, K.C., Kumar, A., Placone, J.K., Fang, C., Wang, K.C., Lu,
S., Pan, M., Hong, A.W., et al. (2018). RAP2 mediates mechanoresponses of
the Hippo pathway. Nature 560, 655–660.
Michael, L.H., Ballantyne, C.M., Zachariah, J.P., Gould, K.E., Pocius, J.S.,
Taffet, G.E., Hartley, C.J., Pham, T.T., Daniel, S.L., Funk, E., and Entman,
M.L. (1999). Myocardial infarction and remodeling in mice: effect of reperfu-
sion. Am. J. Physiol. 277, H660–H668.
Miled, C., Pontoglio, M., Garbay, S., Yaniv, M., and Weitzman, J.B. (2005). A
genomic map of p53 binding sites identifies novel p53 targets involved in an
apoptotic network. Cancer Res. 65, 5096–5104.
Moretti, A., Bellin, M., Welling, A., Jung, C.B., Lam, J.T., Bott-Fl€ugel, L., Dorn,
T., Goedel, A., Ho¨hnke, C., Hofmann, F., et al. (2010). Patient-specific induced
pluripotent stem-cell models for long-QT syndrome. N. Engl. J. Med. 363,
1397–1409.
Nadeau, P.J., Charette, S.J., and Landry, J. (2009). REDOX reaction at ASK1-
Cys250 is essential for activation of JNK and induction of apoptosis. Mol. Biol.
Cell 20, 3628–3637.
Please cite this article in press as: Fiedler et al., MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces
Infarct Size In Vivo, Cell Stem Cell (2019), https://doi.org/10.1016/j.stem.2019.01.013Newby, L.K., Marber, M.S., Melloni, C., Sarov-Blat, L., Aberle, L.H., Aylward,
P.E., Cai, G., de Winter, R.J., Hamm, C.W., Heitner, J.F., et al.; SOLSTICE
Investigators (2014). Losmapimod, a novel p38 mitogen-activated protein ki-
nase inhibitor, in non-ST-segment elevation myocardial infarction: a rando-
mised phase 2 trial. Lancet 384, 1187–1195.
O’Connor, M.S., Safari, A., Liu, D., Qin, J., and Songyang, Z. (2004). The
human Rap1 protein complex and modulation of telomere length. J. Biol.
Chem. 279, 28585–28591.
Oh, H., Wang, S.C., Prahash, A., Sano, M., Moravec, C.S., Taffet, G.E.,
Michael, L.H., Youker, K.A., Entman, M.L., and Schneider, M.D. (2003).
Telomere attrition and Chk2 activation in human heart failure. Proc. Natl.
Acad. Sci. USA 100, 5378–5383.
Ottani, F., Latini, R., Staszewsky, L., La Vecchia, L., Locuratolo, N., Sicuro, M.,
Masson, S., Barlera, S., Milani, V., Lombardi, M., et al.; CYCLE Investigators
(2016). Cyclosporine A in reperfused myocardial infarction: The multicenter,
controlled, open-label CYCLE trial. J. Am. Coll. Cardiol. 67, 365–374.
Patricelli, M.P., Nomanbhoy, T.K., Wu, J., Brown, H., Zhou, D., Zhang, J.,
Jagannathan, S., Aban, A., Okerberg, E., Herring, C., et al. (2011). In situ kinase
profiling reveals functionally relevant properties of native kinases. Chem. Biol.
18, 699–710.
Piot, C., Croisille, P., Staat, P., Thibault, H., Rioufol, G., Mewton, N., Elbelghiti,
R., Cung, T.T., Bonnefoy, E., Angoulvant, D., et al. (2008). Effect of cyclo-
sporine on reperfusion injury in acute myocardial infarction. N. Engl. J. Med.
359, 473–481.
Ronaldson-Bouchard, K., Ma, S.P., Yeager, K., Chen, T., Song, L., Sirabella,
D., Morikawa, K., Teles, D., Yazawa, M., and Vunjak-Novakovic, G. (2018).
Advanced maturation of human cardiac tissue grown from pluripotent stem
cells. Nature 556, 239–243.
Sakata, Y., Hoit, B.D., Liggett, S.B., Walsh, R.A., and Dorn, G.W., 2nd (1998).
Decompensation of pressure-overload hypertrophy in G alpha q-overexpress-
ing mice. Circulation 97, 1488–1495.
Sala, L., Bellin, M., and Mummery, C.L. (2017). Integrating cardiomyocytes
from human pluripotent stem cells in safety pharmacology: has the time
come? Br. J. Pharmacol. 174, 3749–3765.
Sano, M., Wang, S.C., Shirai, M., Scaglia, F., Xie, M., Sakai, S., Tanaka, T.,
Kulkarni, P.A., Barger, P.M., Youker, K.A., et al. (2004). Activation of cardiac
Cdk9 represses PGC-1 and confers a predisposition to heart failure. EMBO
J. 23, 3559–3569.
Schaaf, S., Shibamiya, A., Mewe, M., Eder, A., Sto¨hr, A., Hirt, M.N., Rau, T.,
Zimmermann, W.H., Conradi, L., Eschenhagen, T., and Hansen, A. (2011).
Human engineered heart tissue as a versatile tool in basic research and pre-
clinical toxicology. PLoS ONE 6, e26397.
Sharma, A., Burridge, P.W., McKeithan, W.L., Serrano, R., Shukla, P., Sayed,
N., Churko, J.M., Kitani, T., Wu, H., Holmstro¨m, A., et al. (2017). High-
throughput screening of tyrosine kinase inhibitor cardiotoxicity with human
induced pluripotent stem cells. Sci. Transl. Med. 9, eaaf2584.
Silva, J.M., Li, M.Z., Chang, K., Ge, W., Golding, M.C., Rickles, R.J., Siolas, D.,
Hu, G., Paddison, P.J., Schlabach, M.R., et al. (2005). Second-generation
shRNA libraries covering the mouse and human genomes. Nat. Genet. 37,
1281–1288.
Sivasubramanian, N., Coker, M.L., Kurrelmeyer, K.M., MacLellan, W.R.,
DeMayo, F.J., Spinale, F.G., andMann, D.L. (2001). Left ventricular remodeling
in transgenic mice with cardiac restricted overexpression of tumor necrosis
factor. Circulation 104, 826–831.
Song, W., Dyer, E., Stuckey, D.J., Copeland, O., Leung, M.C., Bayliss, C.,
Messer, A., Wilkinson, R., Tremoleda, J.L., Schneider, M.D., et al. (2011).
Molecular mechanism of the E99K mutation in cardiac actin (ACTC Gene)
that causes apical hypertrophy in man and mouse. J. Biol. Chem. 286,
27582–27593.Stuckey, D.J., McSweeney, S.J., Thin, M.Z., Habib, J., Price, A.N., Fiedler,
L.R., Gsell, W., Prasad, S.K., and Schneider, M.D. (2014). T1 mapping detects
pharmacological retardation of diffuse cardiac fibrosis in mouse pressure-
overload hypertrophy. Circ Cardiovasc Imaging 7, 240–249.
Su, Y.C., Han, J., Xu, S., Cobb, M., and Skolnik, E.Y. (1997). NIK is a new
Ste20-related kinase that binds NCK and MEKK1 and activates the SAPK/
JNK cascade via a conserved regulatory domain. EMBO J. 16, 1279–1290.
Subramaniam, A., Jones, W.K., Gulick, J., Wert, S., Neumann, J., and
Robbins, J. (1991). Tissue-specific regulation of the alpha-myosin heavy chain
gene promoter in transgenic mice. J. Biol. Chem. 266, 24613–24620.
Taira, K., Umikawa, M., Takei, K., Myagmar, B.E., Shinzato, M., Machida, N.,
Uezato, H., Nonaka, S., and Kariya, K. (2004). The Traf2- and Nck-interacting
kinase as a putative effector of Rap2 to regulate actin cytoskeleton. J. Biol.
Chem. 279, 49488–49496.
US Food and Drug Administration (2018). Novel drug approvals for 2018.
https://www.fda.gov/drugs/developmentapprovalprocess/druginnovation/
ucm592464.htm.
Vitorino, P., Yeung, S., Crow, A., Bakke, J., Smyczek, T., West, K., McNamara,
E., Eastham-Anderson, J., Gould, S., Harris, S.F., et al. (2015). MAP4K4 regu-
lates integrin-FERM binding to control endothelial cell motility. Nature 519,
425–430.
Weinberger, F., Mannhardt, I., and Eschenhagen, T. (2017). Engineering car-
diac muscle tissue: A maturating field of research. Circ. Res. 120, 1487–1500.
Whelan, R.S., Kaplinskiy, V., and Kitsis, R.N. (2010). Cell death in the patho-
genesis of heart disease: mechanisms and significance. Annu. Rev. Physiol.
72, 19–44.
White, B.J., Tarabishy, S., Venna, V.R., Manwani, B., Benashski, S.,
McCullough, L.D., and Li, J. (2012). Protection from cerebral ischemia by inhi-
bition of TGFb-activated kinase. Exp. Neurol. 237, 238–245.
Wilding, J.L., and Bodmer, W.F. (2014). Cancer cell lines for drug discovery
and development. Cancer Res. 74, 2377–2384.
Xue, Y., Wang, X., Li, Z., Gotoh, N., Chapman, D., and Skolnik, E.Y. (2001).
Mesodermal patterning defect in mice lacking the Ste20 NCK interacting ki-
nase (NIK). Development 128, 1559–1572.
Yang, Y.M., Gupta, S.K., Kim, K.J., Powers, B.E., Cerqueira, A., Wainger, B.J.,
Ngo, H.D., Rosowski, K.A., Schein, P.A., Ackeifi, C.A., et al. (2013). A small
molecule screen in stem-cell-derived motor neurons identifies a kinase inhib-
itor as a candidate therapeutic for ALS. Cell Stem Cell 12, 713–726.
Yao, Z., Zhou, G., Wang, X.S., Brown, A., Diener, K., Gan, H., and Tan, T.H.
(1999). A novel human STE20-related protein kinase, HGK, that specifically ac-
tivates the c-Jun N-terminal kinase signaling pathway. J. Biol. Chem. 274,
2118–2125.
Yazawa, M., Hsueh, B., Jia, X., Pasca, A.M., Bernstein, J.A., Hallmayer, J., and
Dolmetsch, R.E. (2011). Using induced pluripotent stem cells to investigate
cardiac phenotypes in Timothy syndrome. Nature 471, 230–234.
Yu, J., Vodyanik, M.A., Smuga-Otto, K., Antosiewicz-Bourget, J., Frane, J.L.,
Tian, S., Nie, J., Jonsdottir, G.A., Ruotti, V., Stewart, R., et al. (2007). Induced
pluripotent stem cell lines derived from human somatic cells. Science 318,
1917–1920.
Yue, J., Xie, M., Gou, X., Lee, P., Schneider, M.D., and Wu, X. (2014).
Microtubules regulate focal adhesion dynamics through MAP4K4. Dev. Cell
31, 572–585.
Zhang, D., Gaussin, V., Taffet, G.E., Belaguli, N.S., Yamada, M., Schwartz,
R.J., Michael, L.H., Overbeek, P.A., and Schneider, M.D. (2000). TAK1 is acti-
vated in the myocardium after pressure overload and is sufficient to provoke
heart failure in transgenic mice. Nat. Med. 6, 556–563.
Zohn, I.E., Li, Y., Skolnik, E.Y., Anderson, K.V., Han, J., and Niswander, L.
(2006). p38 and a p38-interacting protein are critical for downregulation of
E-cadherin during mouse gastrulation. Cell 125, 957–969.Cell Stem Cell 24, 1–13, April 4, 2019 13
Please cite this article in press as: Fiedler et al., MAP4K4 Inhibition Promotes Survival of Human Stem Cell-Derived Cardiomyocytes and Reduces
Infarct Size In Vivo, Cell Stem Cell (2019), https://doi.org/10.1016/j.stem.2019.01.013STAR+METHODSKEY RESOURCES TABLEREAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Mouse monoclonal anti-ACTN2 Sigma-Aldrich EA-53: A7811; RRID:AB_476766
Mouse monoclonal anti-FLAG epitope Sigma-Aldrich M2; RRID:AB_262044
Mouse monoclonal anti-HA epitope Santa Cruz F-7; RRID:AB_627809
Mouse monoclonal anti-MAP4K4 Abcam (Figure 1); CST (Figure 5) ab56569; RRID:AB_944156 (Figure 1);
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DMEM, high glucose, GlutaMAX
supplement
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supplement, pyruvate
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DMX-5804 This paper PubChem accession number 98666
Doxorubicin Calbiochem CAS 23214-92-8
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Dulbecco’s Modified Eagle’s
Medium (DMEM) Base, without glucose,
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pyruvate and sodium bicarbonate
Sigma-Aldrich D5030
F1386-0303 Domainex CAS 287177-12-2
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FCCP (carbonyl cyanide-4-phenylhydrazone) Abcam CAS 370-86-5
Fibrinogen Sigma-Aldrich F8630
Fibronectin, bovine plasma Sigma-Aldrich F1141
GNE-495 Domainex CAS 1449277-10-4;
https://www.ncbi.nlm.nih.gov/
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Hoescht 33342 Molecular Probes CAS 23491-52-3
Horse serum GIBCO 26050
Human MAP4K4 kinase domain (aa 1-328) Invitrogen PV3687
HyClone defined fetal bovine serum GE Healthcare Life Science SH30070.03
iCell Cardiomyocytes Maintenance Medium Cellular Dynamics CMC-100-010-001
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Metoprolol (Succinate or tartrate) Sigma-Aldrich CAS 56392-17-7
Nec-1 s (7-ClO-Nec-1) Merck CAS 852391-15-2
Oligomycin A Abcam CAS 1404-19-9
Penicillin/streptomycin (10,000 U mL1) GIBCO 15140
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Texas Red-X succinimidyl ester Molecular Probes F-6162
Critical Commercial Assays
Ames genotoxicity reverse mutation assay Cyprotex https://www.cyprotex.com/
toxicology/genotoxicity/amestest
ApopTag Plus Fluorescein In Situ Apoptosis
Detection Kit
Millipore S7111
ArrayScan VTI High Content Screening
platform
Cellomics N/A
Cardiovascular ADR Eurofins Cerep N/A
CellTiter-Glo Promega G7570
CellTox Green Promega G8741
CLARIOstar with Atmospheric Control Unit BMG Labtech N/A
EHT Contraction Analyzer EHT Technologies GmbH A0001
EHT silicone racks EHT Technologies GmbH C0001
EHT Teflon spacers EHT Technologies GmbH C0002
FLIPR Tetra Molecular Devices N/A
HTRF Transcreener ADP CisBio Bioassays N/A
Human cardiac troponin I AlphaLISA Perkin Elmer AL295C




Kinase enrichment kit Thermo Fisher Scientific 88310
Kinase inhibitor selectivity profiling International Centre for Kinase Profiling,
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REAGENT or RESOURCE SOURCE IDENTIFIER
Kinase inhibitor selectivity profiling Reaction Biology www.reactionbiology.com/
webapps/site/KinaseDetail.aspx
Microsome stability Cyprotex N/A
MitoXpress Intra Intracellular Oxygen Assay Agilent MX-300-4
Pharmacokinetic profiling Pharmidex N/A
PHERAstar Plus BMG Labtech N/A
SafetyScreen44 Eurofins Cerep P270
Seahorse XFe24 Analyzer Agilent N/A
Seahorse XF24 FluxPak Agilent 100850-001
Deposited Data
DMX-5804 structure PubChem DMX-5804; accession number 98666
Experimental Models: Cell Lines














Mouse: FVB/N Tg(Myh6-Map4k4) This paper N/A
Mouse: FVB/N Tg(Myh6-Gnaq)25Gwd Gerald Dorn https://www.ncbi.nlm.nih.gov/
pubmed/9576430
Mouse: FVB/N Tg(Myh6-Tnfa) Douglas Mann https://www.ncbi.nlm.nih.gov/
pubmed/11502710
Oligonucleotides
GIPZ shRNAmirs: human MAP4K4 Open Biosystems V2LHS 68219, V2LHS 202781,
V2LHS 201856
qPCR primer: human GAPDH Thermo Fisher Scientific 4333764F
qPCR primer: human MAP4K4 Thermo Fisher Scientific Hs00377415 m1
qPCR primer: human MINK1 Thermo Fisher Scientific Hs01093259 m1
qPCR primer: human TNIK Thermo Fisher Scientific Hs00323234 m1
qPCR primer: mouse Col1a1 Thermo Fisher Scientific Mm00801666 g1
qPCR primer: mouse Ctgf Thermo Fisher Scientific Mm01192932 g1
qPCR primer: mouse Fn1 Thermo Fisher Scientific Mm01256744 m1
qPCR primer: mouse Postn Thermo Fisher Scientific Mm00450111 m1








Plasmid: pAd-Easy-1 Bert Vogelstein https://www.ncbi.nlm.nih.gov/
pubmed/9482916
Plasmid: pCDNA3-FLAG-JNK1 APF Roger Davis https://www.ncbi.nlm.nih.gov/
pubmed/8137421
Plasmid: pCIneo-HA-TNIK Ken-ichi Kariya https://www.ncbi.nlm.nih.gov/
pubmed/15342639
Plasmid: pCL-puro-mU6 Zhou Songyang https://www.ncbi.nlm.nih.gov/
pubmed/15100233
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Plasmid: pClneo-FLAG-TNIK Ken-ichi Kariya http://kenkyushadb.lab.u-ryukyu.ac.jp/
html/100000748_en.html
Plasmid: pCR3.1-FLAG-MAP4K4 Tse-Hua Tan https://www.ncbi.nlm.nih.gov/
pubmed/9890973
Plasmid: pMD2.G Didier Trono Addgene 12259
Plasmid: pShuttleCMV Bert Vogelstein https://www.ncbi.nlm.nih.gov/
pubmed/9482916
Plasmid: psPAX2 Didier Trono Addgene 12260
Software and Algorithms




Prism GraphPad Software Inc https://www.graphpad.com/
scientific-software/prism/
StatView SAS Institute https://sas-statview.software.
informer.com/5.0/
ZEN 2012 (black edition) Zeiss https://www.zeiss.com/microscopy/
int/downloads.html
FieldTemplater Cresset BioMolecular Discovery Ltd https://www.cresset-group.com/
products/forge/fieldtemplater/
FieldScreen Cresset BioMolecular Discovery Ltd https://www.cresset-group.com/
tag/fieldscreen/
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EXPERIMENTAL MODEL AND SUBJECT DETAILS
Human subjects
Male and female human heart samples were generously provided under local ethical permission by Drs. Cris dos Remedios and Paul
Allen (Sydney Human Heart Tissue Bank; University of Sydney ethics committee approval HREC #2012/2814), and by Dr. Guillermo
Torre-Amione (The Methodist Hospital; Baylor College of Medicine ethics committee approval H-15240). Written informed consent
was received from participants prior to inclusion in the study. Diseased hearts were obtained at the time of therapeutic transplanta-
tion. Healthy myocardial samples were obtained from prospective donors for whom no recipient was identified, overlapping the heart
failure samples in age (donor: mean 43.2 y, N = 10, male 3, female 7; dilated cardiomyopathy: mean 44.3 y, N = 14 including 8 familial
cases, male 10, female 4; hypertrophic cardiomyopathy: mean 43.3 y, N = 3, male 1, female 2; ischemic heart disease: mean 51.6 y,
N = 7, male 6, female 1; adriamycin cardiomyopathy: mean 14.5 y, N = 2, male 2, female 0). No systematic difference was seen due to
age or sex; however, the total number of subjects was small and not intended to permit demographic inferences. Tissue samples
were flash frozen in liquid nitrogen immediately after extirpation of the heart.
Animals
All animal procedures were performedwith UKHomeOffice approval (PL 70/6806, 70/7880) or US institutional review (Baylor College
ofMedicine, AN-3049). Animal work performed in the US conforms to theNIHGuide for theCare andUse of Laboratory Animals (DHS
Publication No. 85-23, revised 1985). Animal work performed in the UK conforms to the UKAnimals (Scientific Procedures) Act, 1986,
incorporating Directive 2010/63/EU of the European Parliament. Procedures for the husbandry and housing of animals follow the rec-
ommendations of the Association for Assessment and Accreditation of Laboratory Animal Care and UK Code of Practice for the
Housing and Care of Animals Bred, Supplied or Used for Scientific Purposes. The Imperial Hammersmith campus animal facilities
comprise an SPF animal breeding facility (H2) and a clean facility for experimental surgery and physiology (H1). Biosecurity and
pathogen exclusions are taken from Federation of European Laboratory Animal Science Associations (FELASA) health monitoringe5 Cell Stem Cell 24, 1–13.e1–e12, April 4, 2019
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Dates and bedding (ECO2) and a 12:12 light:dark cycle. Special Diet Services RM1 and RM3 chow were provided for maintenance
and breeders, respectively, ad libitum. Environmental enrichments included small tunnels, chew blocks, and facial tissues. The
maximum housing density for unoperated mice was 7 per cage if < 25 g and 5 per cage ifR 25 g. Following infarction, mice were
typically housed singly, for monitoring. Similarly, animals at Baylor College of Medicine were housed in an SPF facility for breeding
andmaintenance and a clean satellite facility for surgery and physiology, with minor modifications: the light:dark cycle was 14:10, the
diet was Purina Rodent Laboratory Chow 5001, and environmental enrichments were not used at the time. No animals were involved
in previous procedures, drug administration, or testing. Healthy, immunocompetent, male or female mice, aged 8-10 weeks were
investigated as follows. Except where noted, all transgenic experiments were performed using hemizygous mice in an isogenic
FVB/N background.
Ischemia-reperfusion for exploratory biochemical studies was performed in 8-10 week-old FVB/N mice by ligation of the left ante-
rior descending coronary artery (Michael et al., 1999). The ligature was tightened around the vessel and a superimposed 1mm length
of PE-10 polyethylene tubing. For reperfusion, the ligature and tubingwere removed. Ischemia and reperfusionwere substantiated by
the induction of reversible myocardial blanching and electrocardiographic ST segment elevation. The control (‘‘sham’’) operation
comprised anesthesia, thoracotomy, and placement of the ligature without occlusion.
Biomechanical stress was induced by partially occluding the transverse aorta in 8-10 week-old male mice (FVB/N: Figure S1;
C57BL/6: Figure S3) (Sano et al., 2004). The control (‘‘sham’’) operation comprised anesthesia, thoracotomy, and placement of
the ligature without occlusion. Only mice in which Doppler flow measurements confirmed moderate to severe occlusion (right-to-
left carotid artery velocity ratio > 3.5) were analyzed subsequently. The heart weight/body weight ratio, used to verify effective
constriction, increased 20% at 7 d and 35% at 14 d. Doppler echocardiography (Zhang et al., 2000), cardiac MRI (Stuckey et al.,
2014), and pressure-volume loop analysis (Song et al., 2011) were performed as described.
For compound testing in myocardial infarction, 9-10 week-old CD-1 female mice were used instead, given strain-dependent dif-
ferences in the pharmacokinetics of DMX-5804 (unpublished results), and rates for post-MI rupture inmalemice as high as 49% (Gao
et al., 2005). DMX-5804 and the vehicle control were each administered by oral gavage, as two doses (50 mg kg-1 in 1.5% Captisol),
10 hr apart. General anesthesia was induced with 4% isoflurane, then maintained at 2% in 100% O2. Mice were treated subcutane-
ously with 0.024 mg buprenorphine (average, 1.1 mg kg1; Vetergesic, Alstoe Animal Health), intubated, and ventilated using a tidal
volume of 250 mL and respiratory rate of 150 breaths min1 (Hugo-Sachs MiniVent type 845; Harvard Apparatus). After a left
thoracotomy in the fourth intercostal space, the pericardium was removed. A 6-0 polypropylene suture was used to ensnare the
left anterior descending coronary artery (LAD) and tied against a short section of PE-50 polyethylene tubing for 45 min; blood flow
was re-established by removing the tubing, releasing the ligature. Ischemia and reperfusion were substantiated by reversible distal
blanching and ST segment elevation. Mice were allowed to recover in a heated chamber for 20 min, then moved to a normal holding
cage with supplemental heat if necessary.
Transgenic mice
FLAG-tagged wild-type humanMAP4K4 cDNA, provided by Dr Tse-Hua Tan (Yao et al., 1999), was cloned downstream of the 5.5-kb
Myh6 promoter (Subramaniam et al., 1991) for cardiomyocyte-restricted expression. The resulting construct was injected into the
male pronucleus of FVB/N fertilized oocytes, and the injected zygotes were transferred to pseudopregnant females. Four indepen-
dentMyh6-Map4k4 founder lines were generated, with no premature lethality or other overt baseline phenotype. Results shown are
from line 1998, with similar findings from other founders.
Myh6-Gnaq transgenic mice (Sakata et al., 1998) harbor the 1.46 kb wild-typemouseGnaq cDNA cloned downstream of theMyh6
promoter, and were engineered as above; the line Gaq-25, used here, was kindly provided by Dr Gerald Dorn.Myh6-Tnfa transgenic
mice (MHCsTNF) (Sivasubramanian et al., 2001) express wild-type mouse TNFa driven by the Myh6 promoter, engineered analo-
gously, and were kindly provided by Dr Doug Mann.
Cell lines
Human iPSC-CMs were obtained from Cellular Dynamics (iCell; Figures 1 and 3) and Axiogenesis (CorV4.U; Figures 3 and 4) and
cultured in the respective maintenance medium.
METHOD DETAILS
Cell culture
iCell cardiomyocytes were thawed, transferred to Plating Medium, counted using a Vi-CELL XR cell viability analyzer (Beckman
Coulter), and seeded into 24-well plates for RNA collection (60,000 cells well-1; Greiner) or mClear half-area 96-well plates for
gene silencing (10,000 cells well-1; Greiner). Plates were coated with 10 mg ml-1 collagen type I (BD Biosciences). Cells were cultured
in iCell Cardiomyocytes Plating Medium for 2 d and in MaintenanceMedium thereafter. For compound dose-response comparisons,
the cells were deposited in Plating Medium at 10,000 cells well-1 in 0.1% (w/v) gelatin-coated 384-well white Greiner plates and were
cultured as above for 8 d before treatment.
vCor.4U cardiomyocytes were cultured, except where noted, on white (viability) or black (FLIPR) clear-bottom 384-well plates,
treated for 1 hr with 50 mM fibronectin (Sigma-Aldrich). To minimize batch to batch variation, thawed cells first were transferredCell Stem Cell 24, 1–13.e1–e12, April 4, 2019 e6
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at 1000 well-1 for viability assays or 5000 cells well-1 for FLIPR experiments, all in 40 ml well-1 of the maintenance medium. Cells were
cultured in Axiogenesis complete medium followed by incomplete medium, were subjected to oxidative stress ± test compounds on
day 3, and were assayed on day 4 (Figures 4D and 4E). Alternatively, complete mediumwas replaced on day 2 of culture with 40 ml of
DMEM high Glucose (no FCS or pyruvate), followed by removal and replacement of 20 ml every 2 d for 10 d (Figures 4A–4C).
H2O2, menadione (Sigma-Aldrich), doxorubicin (Calbiochem), and C2-ceramide (N-acetyl-D-sphingosine) were used at the indi-
cated concentrations. MAP4K4 inhibitors were serially diluted in DMSO, transferred to an intermediate plate using assay medium
as a diluting agent, and added at a final concentration of 0.1% DMSO. MAP4K4 inhibitors were added to cultured cardiomyocytes
1 hr before the cell death inducers, except where noted, and remained present for the duration of the experiment.
Western blotting
Cells and tissues were lysed in the presence of protease and phosphatase inhibitors (Pierce; Roche), resolved by SDS-polyacryl-
amide gel electrophoresis, and transferred to nitrocellulosemembranes (Schleicher & Schuell; Optitran, GEHealthcare Life Sciences)
for western blotting. Mousemonoclonal antibody toMAP4K4was fromCell Signaling (ab56569). Rabbit antibodies to ERK, phospho-
ERK (Thr202/Tyr204), JNK, phospho-JNK (Thr183/Tyr185), p38 and phospho-p38 (Thr180/Tyr182) were from Cell Signaling. Mouse
antibody to the FLAG epitope (M2) was from Sigma-Aldrich. Mouse antibody to the HA epitope (F-7), rabbit antibody to caspase-3
(H-277) and HRP-conjugated goat antibody to total actin (I-19) were from Santa Cruz Biotechnology. Protein expression was visu-
alized using horseradish peroxidase-conjugated secondary antibodies to IgG (Dako), followed by enhanced chemiluminescence
reagents (Amersham; Pierce; Promega).
For initial studies (Figures S1 and S2), commercially available antibodies against MAP4K4 were inadequate and a polyclonal rabbit
antibody was generated by a reported protocol (Yao et al., 1999). A synthetic peptide was synthesized, corresponding to amino acids
899–920 of mouse MAP4K4 (CNPTNTRPQSDTPEIRKYKKRFN), which are invariant in the rat and human kinases. For immunization,
the peptide was coupled to keyhole limpet hemocyanin via the N-terminal cysteine. The resulting antibodies were affinity-purified on
MAP4K4 peptide-conjugated Sepharose beads. Specificity was confirmed in HEK293T cells transiently transfected using Effectene
(QIAGEN) and 1 mg of pCR3.1-FLAG-MAP4K4 (Yao et al., 1999), versus pCIneo-HA-TNIK or pClneo-FLAG-TNIK (TRAF2- and NCK-
interacting kinase (Taira et al., 2004).
RNA interference
Human iPSC-CMs (iCell) were transduced with Hannon-Elledge microRNA-adapted shRNAs, a system optimized for efficient gene
suppression (Silva et al., 2005). GIPZ shRNAmir sequences targeting theMAP4K4 coding sequence (Open Biosystems) were incor-
porated into lentivirus using a second-generation packaging system from Didier Trono (psPAX2, pMD2.G). Thawed cells were
cultured for 2 d in iCell Cardiomyocytes Plating Medium then for 5 d in iCell Cardiomyocytes Maintenance Medium. Cells were trans-
duced for 6 hr (day 7), using serum-free DMEM, 8 mg ml-1 polybrene, a multiplicity of infection of 50, and non-silencing GIPZ
(RHS4348) as the negative control. Cells were then cultured for 2 d in iCell Cardiomyocytes Maintenance Medium, and maintained
for 2 d in low glucose DMEM containing 2% FBS. Cells were harvested for qPCR on day 11 or treated with H2O2 at the indicated
concentrations, and assayed 24 hr later (day 12).
Quantitative real-time PCR (qRT-PCR)
RNA extraction was performed using RNAeasy Fibrous Tissue Mini Kits (QIAGEN) for mouse hearts and PureLink RNA Micro Scale
Kits (Life Technologies) for cultured cells. RNA quality and quantity were assessed using a NanoDrop 1000 spectrometer (Thermo
Fisher Scientific). RNA was converted to cDNA using High-Capacity cDNA Reverse Transcription Kits (Applied Biosystems).
qRT-PCR was performed using TaqMan Gene Expression Assays, MicroAmp Optical 384-well plates, 2X TaqMan Gene Expression
Master Mix, and a 7500 Real-Time PCR System (Applied Biosystems).
Immune complex kinase assays
MAP4K4 was precipitated using M2 antibody to the FLAG epitope, or antibody to endogenous MAP4K4, and protein G-Sepharose.
Precipitates werewashed twice in lysis buffer, twicewith 500mMLiCl, 100mMTris-HCl, pH 7.6, 0.1%Triton X-100, twicewith kinase
buffer (20 mM MOPS, pH 7.6, 2 mM EGTA, 10 mM MgCl2, 1 mM dithiothreitol, 0.1% Triton X-100, 1 mM Na3VO4), and were then
mixed with 10 mg of myelin basic protein (Invitrogen) as substrate, 15 mM ATP, and 10 mCi [g-32P]ATP in 30 mL of kinase buffer
for 30 min at 30C (Yao et al., 1999). His-MKK6 was used as the substrate for TAK1 (Zhang et al., 2000). Reaction mixtures were
resolved by SDS-polyacrylamide gel electrophoresis, then were analyzed by western blotting and autoradiography.
Human cardiac muscle cell death
To measure loss of membrane integrity, iCell hiPSC-CMs were co-stained for 15 min at 37C with 0.3 mMDRAQ7 (Biostatus), a cell-
impermeable dye, and with 0.8 mM Hoescht 33342 (Molecular Probes), as the membrane-permeable dye. Dyes were removed and
the nuclear fluorescence scored (typically, 15,000-20,000 cells well-1) using a Cellomics ArrayScan VTI High Content Screening plat-
form. The line harbors a cardiomyocyte-specific Myh6-driven reporter gene for monomeric red fluorescent protein (RFP), enabling
cell death to be scored exclusively in themyocyte population. Successfully transduced cells were identified on the basis of TurboGFP
fluorescence. Images were analyzed with Developer XD, version 2.11 (Definiens).e7 Cell Stem Cell 24, 1–13.e1–e12, April 4, 2019
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For cell-based dose-response experiments, MAP4K4 inhibitors were prepared in 96-well polypropylene plates as serial dilutions in
DMSO of 10 mM stock solutions. To a sterile 96-well intermediate plate, 1 ml of each well was added to 99 ml of medium, the samples
were mixed, and 5 ml well-1 from the intermediate plate were transferred to the cultured cells (final concentration, 0.1% DMSO; final
top concentration of inhibitor, 10 mM). Assay plates were gently centrifuged then incubated for 1 hr at 37C. The death triggers mena-
dione, H2O2 and doxorubicin were prepared fresh on the day of treatment at 10x the final concentrations and 5 ml well
-1 were added
as appropriate. Assay plates were gently centrifuged and then incubated at 37C for the duration of treatment.
CellTiter-Glo (CTG) luminescent cell viability assay
Assay plates were removed from the incubator, allowed to reach room temperature, inoculated with 20 ml well-1 CTG reagent (Prom-
ega), and gently agitated for 30 min. Prior to adding CTG, 2 ml well-1 of the culture medium was removed and placed into a white
384-well low volume plate for measurement of cardiac troponin release by AlphaLISA (below). Luminescence due to ATP, propor-
tional to cell number, was captured on a PHERAstar Plus microplate reader (BMG Labtech). Normalized values were plotted against
the log concentration of death signal or inhibitor, and a 4-parameter fit was used to identify IC50 and EC50, respectively.
Troponin I detection
Aliquots of medium collected after cells’ treatment with death signals and MAP4K4 inhibitors were incubated at room temperature
with AlphaLISA human cardiac troponin I detection reagents (PerkinElmer): sequentially, anti-Troponin I acceptor beads for 1 hr, bio-
tinylated antibody to troponin I for 1hr, and streptavidin (SA)-coated donor beads for 30 min. The AlphaLISA signal was acquired us-
ing the Pherastar Plus plate reader. All detection reagents were diluted in 1X AlphaLISA Immunoassay Buffer and a serially diluted
analyte standard was used to quantitate the concentration of human cardiac troponin I (pg ml-1).
Hypoxia-reoxygenation assay
vCor.4U cells were plated at 10,000 well-1 in Cor.4U medium using black, clear-bottom 96-well plates pre-treated with Geltrex
(GIBCO). After incubation overnight at 37C, the media was replaced with phenol red-free DMEM (GIBCO) supplemented with
2% FCS, 2 mM L-glutamate, 1 mM pyruvate and 10 mM D-galactose. DMX-5804 prepared in DMSO and CellTox Green (Promega)
were added and incubated for 1 hr at 37C. A breathable seal (AeraSeal) was added to the plate before transferring to a CLARIOstar
plate reader (BMG Labtech) equipped with an atmospheric control unit. Oxygen concentration ramping was executed as follows
(% O2, hr), at 37C and 5% CO2. Fluorescence measurements (lex/em 483-14/530-30) were taken using the multiple scan and direct
bottom features (5 positions read), and matrix averaging of each position every 20 min. Data were blank corrected, averaged (n = 2)
and subjected to exponential smoothing with a damping factor of 0.3.
Ion channel safety screening
Electrophysiological recordings (Apconix) were performed using aChinese Hamster Ovary cell line stably expressing full length hERG
or hNaV1.5, or HEK293 cells stably expressing full length hCaV1.2. Single cell currents were measured in whole-cell configuration at
21-23C using a Patchliner (Nanion Technologies). The internal solution for hERG contained (mM): 120 KF, 20 KCl, 10EGTA, 10
HEPES (pH 7.3). The internal solution for hNaV1.5 and CaV1.2 contained (mM): 140 CsF, 1 EGTA, 10 NaCl, 10 HEPES (pH 7.3).
The external solution contained (mM): 138 NaCl, 4.5 KCl, 1.8 CaCl2, 1.0 MgCl2, 10 HEPES, 10 glucose (pH7.4). Late Na
+ currents
were activated with 50 mM veratridine. Cells were clamped at a holding potential of 80 mV before a depolarising step appropriate
for each channel. Currents measured from the step were referenced to the holding current. Compounds were then incubated for
2-3 min prior to a second measurement using an identical pulse train.
Ames genotoxicity reverse mutation assay
Approximately 107 bacteria were exposed in triplicate to the test agent (six concentrations, 7.8-250 mgml-1), a vehicle control (vehicle)
and a positive control for 90min in low-histidinemedium (sufficient for about 2 doublings.) The strains usedwere S. typhimurium TA98
(hisD3052, rfa, uvrB / pKM101; detects frameshift mutations) and TA100: hisG45, rfa, uvrB / pKM101; detects base-pair substitu-
tions). The cultures were then diluted into indicator medium lacking histidine, dispensed into 384-well plates, and incubated for
48 hr at 37C. The test was performed in the absence and presence of S9 metabolic activation, to identify pro-mutagens as well
as directly acting mutagens. Only cells that underwent reversion grow, resulting in a color change. A two-fold increase over the
vehicle control in the number of colonies indicates a positive response.
In vitro MAP4K4 kinase activity assay
MAP4K4 kinase activity was monitored using the CisBio HTRF Transcreener ADP assay, a competitive immunoassay with a repro-
ducible Z’ > 0.6. In the detection step, endogenous ADP and d2-labeled ADP compete for binding an anti-ADP monoclonal antibody
labeled with Eu3+ cryptate. A ratiometric fluorescent readout is used at 665 and 620 nm. Reactions were performed in the presence of
1% DMSO with ATP added at Km (10 mM), 0.5 nM human MAP4K4 kinase domain (Invitrogen), 1 mM biotin-myelin basic protein as
substrate (Invitrogen), and extension of reaction time to 2 h. Assays were run in Greiner low volume plates with a final reaction volume
of 10 ml. Percent inhibition was calculated from 100%activity of MAP4K4 (DMSOonly) and 0%activity (no enzyme added). Data were
either reported as % inhibition at a single dose or as pIC50 values derived from dose response curves (pIC50 = -log[IC50]).Cell Stem Cell 24, 1–13.e1–e12, April 4, 2019 e8
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(a) Hardware and software. The Field Point Pharmacophore was created using theMacOS X 10.6 version of FieldTemplater v. 2.1.1
running on aMacPro (3x2.97GHz 4-Core Intel Xeon). The virtual screenwas run at Cresset BioMolecular Discovery Ltd (https://www.
cresset-group.com). Blaze v.10.0wasmounted on a Linux (Debian) Cluster containing 50 Intel and AMDnodes andwas usedwith the
input seed field to search 370M field patterns from 3.7M commercially available molecules, 100 conformations each. Each search
took 12-15 CPU hours, returning a field similarity with the seed input for every molecular entry. The 200 with highest similarity
were used as the virtual screening ‘‘hit list’’ in subsequent analysis and acquisition. Overlays were examined using Forge v.10.0
on Macintosh or PC desktops.
(b) Creation of the field point pharmacophore. FieldTemplater v. 2.11 was used to derive the field point pharmacophore for
the template compounds, using the inbuilt conformation hunter and XED molecular mechanics force fields. Using an upper
threshold of 6 kcal mol-1 above the calculated global energy minimum gave 2 conformations of PD-407824; 4 of GW5074; and
1 of Kenpaullone, reflecting the low number of rotatable bonds in these molecules. Each conformation was then equipped with
four types of molecular field points: the extrema of positive and negative electrostatic regions, hydrophobic regions, and areas
of maximum van der Waals attraction. The field points were calculated in terms of the interaction of appropriate charged and
neutral probes at and beyond the molecular surface and were visualized as colored spheres at the position of the extrema, sized
according to their magnitude. Each conformation was compared in turn to all those of another molecule. Initial alignments were
generated on the basis of distances, sizes and types of field point and were grouped into ‘‘cliques,’’ whose scores reflect the size
of clique and the field points within it. For top scoring alignments, the field points of one conformation were used to sample the full
field of the second molecule, and the process was then repeated for the second on the first. The average of the two scores was
taken as the score for that pair, normalized to give a Dice field similarity metric, and the process was repeated over the complete
set of compounds. For the three template compounds here, FieldTemplater identified five potential solutions, one of which was
used as the seed for virtual screening.
(c) Virtual Screening with FieldScreen. Four screens were run, one with the complete template and a further three independent
searches with the individual components, credibly the bioactive conformations of each. In each case, the relevant field point pattern
was compared to those of 100 conformations each from 3.7M commercially available molecules. The scoring function reflects the
electrostatic and steric similarity of compounds within the database to those of the seed pharmacophore and was used to rank
the virtual hits. The 40 top available compounds were purchased from the Enamine Screening Collection (https://enamine.net) or
Chembridge Express Pick (https://www.chembridge.com), were validated by 1H nuclear magnetic resonance and mass spectros-
copy, and were assessed for activity against human MAP4K4 by the HTRF Transcreener ADP assay.
Selectivity and microsomal stability assays
Kinase selectivity profiling was performed by the International Centre for Kinase Profiling, MRC Protein Phosphorylation and Ubiq-
uitylation Unit (141 kinases; Premier Screen, http://www.kinase-screen.mrc.ac.uk), using a [g-33P]ATP filter binding assay (Bain et al.,
2007). Compounds were screened at 1 mM. For key hits, pIC50 values were then determined by HTRF as above. More complete
kinome profiling was performed by Reaction Biology (376 kinases). Stability in mouse and human liver microsomes was determined
by Cyprotex.
Analytical chemistry
Compounds were characterized by liquid chromatography–mass spectrometry (LC-MS) using Method A or B below and/or nuclear
magnetic resonance (NMR).
Method A: Phenomenex Luna C18(2), 3 mm, 503 4.6 mm; A = water + 0.1% formic acid; B =MeOH + 0.1% formic acid; 45C;%B:
0.0 min 5%, 1.0 min 37.5%, 3.0 min 95%, 3.5 min 95%, 3.51 min 5%, 4.0 min 5%; 2.25 mL min-1.
Method B: Phenomenex Gemini NX-C18, 5 mm, 150 3 4.6 mm; A = water + 0.1% formic acid; B = MeOH + 0.1% formic acid;
40C; %B: 0.0 min 5%, 0.5 min 5%, 7.5 min 95%, 10.0 min 95%, 10.10 min 5%, 13 min 5%; 1.5 mL min-1.
NMR spectra were obtained on Bruker Advance 400, Bruker DRX 400 or Jeol 400 ECS NMR spectrometers at room temperature
unless otherwise stated. 1H NMR spectra are reported in ppm and referenced to the residual solvent peaks e.g., DMSO-d6
(2.50 ppm), CDCl3 (7.26 ppm) or CD3OD (3.31 ppm).
Preparative High Performance Liquid Chromatography (HPLC)
Mass-directed purification was performed to isolate DMX-5804 and a number of the intermediates, using preparative reversed-
phase HPLC-MS (Phenomenex Luna C18(2), 5 mm, 100 3 21.2 mm) and pH 2 as below.
Method C: A = water + 0.025% formic acid; B = acetonitrile, 30C;%B: 0.0 min Initial 10%, 10.0 min 20%, 20.0 min 30%, 30.0 min
50%, 40.0 min 75%; 40.0 mL min-1.
Method D: A = water + 0.1% formic acid; B = MeOH + 0.1% formic acid; 20C; %B: 0.0 min Initial 45%, 0.1 min % as per Initial,
7.0 min 85%, 9.0 min 95%, 10.0 min 95%, 10.1 min back to Initial %; 12.0 min Initial %; 20.0 mL min-1.
Synthesis of 5-[4-(2-Methoxy-ethoxy)-phenyl]-7-phenyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (DMX0005804)
See Methods S1 for illustrations of synthetic route and key structures.e9 Cell Stem Cell 24, 1–13.e1–e12, April 4, 2019
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To a solution of 4-chloro-5-iodo-7H-pyrrolo[2,3-d]pyrimidine (1) (15.0 g, 53.5 mmol) in dimethylformamide (100 mL) was added
2-phenyl-1,3,2-dioxoborinone (2) (17.3 g, 107.0 mmol), copper (II) acetate monohydrate (21.4 g, 107.0 mmol), and activated molec-
ular sieves (4A˚, 0.4 g), followed by addition of triethylamine (22.3 mL, 160.4 mmol). The resulting reaction mixture was stirred at 60C
for 24 hr then cooled to room temperature and the solvent concentrated in vacuo. The crude residue was dissolved in dichlorome-
thane (300mL) and quenchedwith saturated ethylenediaminetetraacetic acid (EDTA) solution (100mL). The separated aqueous layer
was extracted with dichloromethane (2 3 100 mL), then the combined organic layer was dried over anhydrous sodium sulfate,
filtered, and concentrated in vacuo. The crude compoundwas purified by reversed-phase preparative HPLC-MS (MethodC) to afford
4-chloro-5-iodo-7-phenyl-7H-pyrrolo[2,3-d]pyrimidine (3) as an off-white solid (6.2 g, 33%).
1H NMR (400MHz, DMSO-d6): d 8.70 (s, 1H), 8.39 (s, 1H), 7.81-7.77 (m, 2H), 7.61-7.56 (m, 2H), 7.47 (tt, J = 7.8, 1.4 Hz, 1H); LC-MS.
Rt 3.37 min (Method A); (ESI
+) m/z 356, 358 [M+H]+.
Step 2: 5-Iodo-7-phenyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (4)
A suspension of 4-chloro-5-iodo-7-phenyl-7H-pyrrolo[2,3-d]pyrimidine (4.0 g, 11.3 mmol) and sodium acetate (1.9 g, 22.5 mmol) in
acetic acid (25 mL) was heated at 100C for 15 h. The reaction mixture was concentrated in vacuo. The crude solid was diluted with
water and the resulting solid was filtered and dried under vacuum to afford 5-Iodo-7-phenyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-
one (4) as a yellow solid (3.68 g, 97%).
1H NMR (400 MHz, DMSO-d6): d 12.16 (br s, 1H), 7.95 (s, 1H), 7.70-7.66 (m, 2H), 7.68 (s, 1H), 7.56-7.51 (m, 2H), 7.41 (tt, J = 7.3
1.4 Hz, 1H); HPLC-MS. Rt 2.79 min, (Method A); (ESI+) m/z 338 [M+H]+.
Step 3: 5-[4-(2-Methoxy-ethoxy)-phenyl]-7-phenyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (DMX0005804)
A mixture of 5-iodo-7-phenyl-3,7-dihydro-pyrrolo[2,3-d]pyrimidin-4-one (4) (180 mg, 0.534 mmol), 2-(4-(2-methoxyethoxy)phenyl-
4,4,5,5-tetramethyl-1,3,2-dioxaborolane (5) (186 mg, 0.67 mmol), Pd(dppf)Cl2 (43.6 mg, 0.05 mmol) and potassium carbonate
(148 mg, 1.07 mmol) in dioxane:H2O (3 mL, 9:1) was de-oxygenated for 5 mins then heated in a microwave reactor at 120
C for a
total of 90 min. The reaction was repeated on the same scale with heating in a microwave for 2 h. The combined reaction mixture
was filtered through celite 545 and washed with methanol. The filtrate was concentrated in vacuo. The crude solid was diluted
with dichloromethane and water and the layers separated via a phase separator cartridge. The combined organics were concen-
trated in vacuo. The crude solid was purified by silica gel chromatography, eluting with 0%–7.5% methanol/dichloromethane, fol-
lowed by reversed-phase preparative HPLC-MS (Method D). A final purification using silica gel chromatography was carried out
by eluting with 0%–5% methanol/dichloromethane to afford 5-[4-(2-Methoxy-ethoxy)-phenyl]-7-phenyl-3,7-dihydro-pyrrolo[2,3-d]
pyrimidin-4-one (DMX0005804) as a white solid (70 mg, 18%).
1H NMR (400 MHz, DMSO-d6): 12.13 (br s, 1H), 7.95 (s, 1H), 7.93 (d, J = 8.8 Hz, 2H), 7.78-7.75 (m, 2H), 7.73 (s, 1H), 7.58-7.55
(m, 2H), 7.42 (tt, J = 7.6, 1.3 Hz, 1H), 6.95 (d, J = 8.8 Hz, 2H), 4.13-4.11 (m, 2H), 3.69-3.66 (m, 2H), 3.32 (s, 3H); 13C NMR
(400 MHz, DMSO-d6): 158.6, 157.2, 147.7, 144.3, 137.2, 129.5, 129.1, 127.0, 125.8, 124.5, 120.7, 120.6, 113.9, 106.0, 70.4, 66.8,
58.1; LC-MS. Rt 7.66 min (Method C); (ESI
+) m/z 362 [M+H]+.
Human cardiac muscle cell function
Calcium transients in hiPSC-CMs were assessed using FLIPR Tetra instrumentation and Early Tox Cardiotoxicity kits (Molecular De-
vices). vCor.4U cells were subjected to graded concentrations of menadione and theMAP4K4 inhibitors as described for the viability
assays. Compound concentrations and time course are denoted in the figure and figure legend. Vehicle controls were used
throughout. Cells were incubated for 2-3 hr at 37C in 5% CO2, using 3 mL well
-1 of EarlyTox Cardiotoxicity Kit concentrate as the
fluorescent calcium indicator dye. Plates were then removed from the incubator and allowed to reach room temperature. Intracellular
calcium oscillations were monitored using a FLIPR Tetra system with excitation LED bank 470-495 nm and emission filter set
515-575 nm (Molecular Devices). Fluorescence intensity signals were acquired for 600 reads at 1.2 ms intervals. Beat frequency,
median peak height, median peak width and total peak area were calculated and compared with the baseline control and with mena-
dione alone. Protection of calcium cycling by DMX-4804 was confirmed in 3 independent experiments with overlapping conditions,
and results are shown for a full dose-response study, analyzing 4 wells for each point.
Mitochondrial function in hiPSC-CMs was determined using a Seahorse XFe24 Analyzer. vCor.4U cells (60,000 well-1) were trans-
ferred to 0.1% gelatin-coated XF24 plates and maintained for 5 d, as described above. On day 6, DMX-5804 was added 45 min prior
to challenge with menadione for 2 h. The medium was replaced 1 hr before the assay, using bicarbonate-free Seahorse assay
medium (8.3 g L-1 DMEM Base (Sigma-Aldrich), 10 mM glucose, 2 mM L-alanyl-L-glutamine dipeptide (Glutamax-1, GIBCO),
1 mM sodium pyruvate (GIBCO), pH 7.4). Cells were maintained at 37C without supplemental CO2 starting 1 hr before the assay
(IL10 incubator, VWR). For each state measured, three assay cycles were performed (4 min mixing, 2 min wait, and 2 min measure-
ment periods, with readings every 15 s). The basal oxygen consumption rate (OCR) and extracellular acidification rate (ECAR) were
determined, followed by sequential injection of 1 mM oligomycin A (Abcam) to inhibit ATP synthase, 0.5 mM carbonyl cyanide-4-
phenylhydrazone (FCCP; Abcam) to uncouple oxidative phosphorylation, and 1 mM antimycin A/rotenone (Sigma, Abcam) to inhibit
mitochondrial complex III and I. For each condition, 12 wells were tested, comprising 4 independent experiments.Cell Stem Cell 24, 1–13.e1–e12, April 4, 2019 e10
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Fibrin-based hEHTs were generated between flexible silicone posts as described (Breckwoldt et al., 2017; Hansen et al., 2010), with
minor modifications. 1.8 mL well-1 of 2% agarose in PBS was pipetted into 24-well plates, Teflon spacers (EHT Technologies) were
placed inside eachwell as a castingmold, and the agarose was left to set for 15min. The spacers were removed from eachwell, and a
pair of polydimethylsiloxane posts was inserted from above (EHT Technologies: Young’s modulus 1.7 mPa, length 10 mm, radius,
0.5 mm). VCor.4U cells (4 3 106) were resuspended in 400 mL of master mix (340 mL DMEM (Biochrom), 10% heat-inactivated fetal
calf serum (GIBCO), 2mMglutamine (Life Technnologies), 1% penicillin/streptomycin (GIBCO); 60 mL 2x DMEM (GIBCO), 20% horse
serum (GIBCO), 2%penicillin/streptomycin). Bovine fibrinogen (Sigma) was added (10 mL: 200mgmL-1, 95 mgmL-1 aprotinin (Sigma),
0.9% NaCl), and 100 mL aliquots were transferred to PCR tubes containing 3 mL of 100 U ml-1 thrombin (Biopur) in 60% PBS. Cell
suspensions then were immediately transferred to the agarose casting molds. After 90 min to allow solidification, 300 mL well-1 of
EHT medium was added (DMEM, 10% horse serum, 0.1% human insulin (Sigma), 0.1% aprotinin), to hydrate the gels for a further
50 min. The hEHTs were then transferred to fresh 24-well plates with 1.5 mL well-1 of EHT medium, which was replaced every
Monday, Wednesday, and Friday for 12 d. Auxotonic force measurements were performed daily by optical tracking (Hansen
et al., 2010) and calculated on the basis of post deflection distance (d), post length (L), post radius (R), and the elastic modulus
(E), using the formula F = 3pER4d4L-3 (Schaaf et al., 2011) and the indicated post parameters. Beating rate and force generation
increased between d 5 and 10 and were stable for at least 7 d thereafter. On day 12, the hEHTs were challenged for 24 hr with mena-
dione, in the absence or presence of DMX-5804. Medium, including DMX-5804, was replenished daily. For each time-course, 4 con-
structs were tested, comprising 4 independent experiments.
Oral PK
In vivo pharmacokinetic profiling was performed in female CD-1 mice, using 3 animals per time point. First, 30% w/v Kleptose as
excipient was dissolved in water and vortexed gently for several min. Next, 30 mg of the test compound was dissolved into
0.6 mL of DMSO, for a concentration of 50 mg ml-1, and 4.5 mL of the Kleptose solution was added to 0.5 mL of the test compound
solution. A precipitate forms, which re-dissolves over 2-5 min, leaving a clear or slightly hazy solution with a final concentration of
5 mg ml-1. The dosing solution is used as soon as practicable, vortexing immediately prior to use. This amount was sufficient formu-
lation for 25 doses of 200 mL (20 gmouse). Compoundswere administered orally at 50mg kg-1, with terminal blood (plasma) sampling
at 10 min, 30 min, 1 h, 2.5 h, 5 h, 10 h, and 20 h.
Target engagement assays
Lysates were prepared and assayed using a desthiobiotin-ATP probe Kinase Enrichment Kit (Thermo Fisher Scientific) (Patricelli
et al., 2011). In brief, tissue samples (100-120 mg) were cut into small pieces and resuspended in 1 mL of Lysis Buffer containing
protease and phosphatase inhibitors. After homogenization (30 s on ice), the lysates were centrifuged (16,000 x g at 4C for
10 min) and a buffer-exchange to Reaction Buffer was performed, to remove endogenous ATPs. Protein concentrations were
measured by the BCA assay (Thermo Fisher Scientific). Compounds were added to 500 mL of lysate at 2 mg/ml in presence of
20 mM MgCl2 and incubated for 10 min at room temperature. The ActivX desthiobiotin-ATP probe (5 mM) was added, and samples
were incubated for 10min. Reactionswere stopped by adding 500 mL of 8MUrea/Lysis Buffer, and labeled kinaseswere captured by
incubating samples with 60 mL of 50%Streptavidin-Agarose beads. Samples were incubated with constant inversion for 2 hr at room
temperature. Samples were centrifuged (1000 x g for 1 min) and washed three times with 500 mL of 4 M Urea/Lysis Buffer. Captured
kinases were eluted by boiling in 30 mL of Laemmli sample buffer for 15 min. Samples were analyzed by western blotting for MAP4K4
and for Src or p38 and were normalized to the capture of the untargeted control kinase.
Histology
To determine infarct size and area at risk, mice were re-intubated after 24 hr of reperfusion, ventilated as previously, and a lateral
thoracotomy was performed to expose the myocardium. The suture around the LAD was re-occluded and 1 mL of 1% Evan blue
solution in saline was infused via the right ventricle. Hearts were rapidly excised, rinsed in PBS and allowed to freeze at 20C
for 20 min. Short axis sections were prepared (1 mm), incubated in 2% 2,3,5-triphenyltetrazolium chloride (TTC) for 15 min, placed
in 4%paraformaldehyde overnight, and rinsed in PBS for 15min before imaging. AARwas calculated as 100%minus the Evans blue-
positive area.
For other histological studies, hearts were pressure-perfused with formalin, dehydrated to 70% ethanol, mounted in paraffin,
sectioned, and stained with hematoxylin and eosin or picrosirius red. For immunostaining, sections were de-paraffinized, dehy-
drated, washed with PBS, and treated with 0.4% Triton-X in PBS. Nuclei were stained with 2.5 mg ml-1 diamidinophenolindole
(DAPI). Alternatively, fixed frozen sections were used. Cleaved DNA (apoptotic cells) was visualized using TUNEL ApopTag Kits (Milli-
pore). Cardiomyocytes were identified using MF20 antibody to sarcomeric myosin heavy chains (MyHC; R&D Systems) (fluorescein-
conjugated: Figure S3C; unconjugated, plus Alexa Fluor-555 anti-mouse IgG: Figure S3H; conjugated and unconjugated mouse
IgG2b were the respective controls). Sections were counterstained with DAPI and treated with Prolong Gold Antifade Mountant
(Life Technologies). Images were captured with a Zeiss Axioplan 2 epifluorescence microscope, LSM-510 inverted confocal micro-
scope, or LSM-780 inverted confocal microscope, using Zeiss ZEN 2012 (black edition) and ImageJ (Fiji) software.e11 Cell Stem Cell 24, 1–13.e1–e12, April 4, 2019
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Ventricular myocytes from 1 to 3 day-old Sprague-Dawley rats were enzymatically dissociated, purified by Percoll gradient centri-
fugation and pre-plating, and cultured as described (Oh et al., 2003). To detect hypodiploid DNA, flow cytometry was performed
(XL or LSRII, BD Biosciences), using propidium iodide to measure DNA content and sampling > 5000 cells for each histogram.
Myocyte identity was confirmed using FITC-conjugated MF-20 antibody to sarcomeric MyHC (R&D Systems). To detect dissipation
of mitochondrial membrane potential (DJm), cells were incubated for 60 min in 5 mg ml-1 5, 50, 6, 6’-tetrachloro-1, 1’, 3, 30-tetraethyl-
benzimidazolyl carbocyanine iodide (DePsipher; R&D Systems). When DJm is intact, mitochondrial uptake and aggregation of the
dye result in red fluorescence; when DJm is disturbed, the dye diffuses to the cytoplasm and reverts to its monomeric green form.
Myocyte identity was confirmed using mouse antibody to sarcomeric tropomyosin (Sigma-Aldrich) conjugated with Texas Red-X
(Molecular Probes).
Adenoviruses
Using pAd-Easy-1 and pShuttleCMV (B. Vogelstein, Johns Hopkins University), we created recombinant adenoviruses expressing
wild-type MAP4K4, dominant-negative mutations of MAP4K4 (K54E, K54R), dominant-negative TAK1 (K63W), and dominant-nega-
tive JNK1 (APF). MAP4K4 is alternatively spliced, with the presence or absence of an SH3-like domain being one potentially important
difference. Here, we used the shorter form, which predominates in cardiac muscle (not shown) and other cell types (Yao et al., 1999).
Kinase-inactive mutations of MAP4K4 were generated by site-directed mutagenesis using wild-type humanMAP4K4 cDNA, with the
FLAG epitope, as template (Yao et al., 1999). Dominant-negative, FLAG-tagged JNK1 (JNK1 APF) cDNA was provided by R. Davis
(University of Massachusetts). Adenovirus encoding dominant-negative p38a (TGY/AGF) with a FLAG epitope tag was provided
by Y. Wang (University of California, Los Angeles), and adenovirus encoding Bcl2 by L. Kirshenbaum (University of Manitoba). Rat
ventricular cardiomyocytes were infected at a multiplicity of infection of 10 for each virus, then cultured in serum-free medium for
24-48 h. Multiplicity of infection was kept constant in each experiment using control virus containing CMV-GFP.
For RNA interference in rat cardiomyocytes, an irrelevant siRNA sequence against GFP (50-GGCTACGTCCAGGAGCGCACC-30)
was obtained and siRNA against rat MAP4K4 was designed using ON-TARGET (both, Dharmacon). Of four sequences tested,
one 50-GGTTGAAAGTGATCTATGG-30 achieved efficient knockdown of co-transfected MAP4K4 (Figure S4B, left). The sequence
was synthesized as a hairpin structure 50-GATCTTTggttgaaagtgatctatggTTCAAGAGAccatagatcactttcaaccTTTTTGGA-30 and in-
serted in a modified pShuttle vector with a MU6 promoter (Z. Songyang, Baylor College of Medicine) (O’Connor et al., 2004). Ade-
noviruses expressing the siRNAs were generated using AdEasy-1. Cardiomyocytes were infected as above for 36 h.
QUANTIFICATION AND STATISTICAL ANALYSIS
Data are reported as the mean ± standard error, using a significance level of p < 0.05. The number of replicates is indicated in the
figure legends; ‘‘N’’ denotes the number of independent experiments and ’’n’’ denotes the number of cultures or number of animals,
as appropriate. Data were analyzed by two-way ANOVA, using Scheffe’s or Bonferroni test for multiple comparisons and Welch’s
t test for pairwise comparisons (StatView 5.0, Abacus Concepts; Prism 5-7, GraphPad). MRI and pressure-volume loops were
analyzed by one-way ANOVA and Neuman-Keuls test. Survival probabilities were analyzed by the Kaplan-Meier method.
DATA AND SOFTWARE AVAILABILITY
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